EA040867B1 - SYSTEMS AND METHODS FOR INTEGRATED AND COMPREHENSIVE CONTROL OF CANNABIS DRUGS - Google Patents

Description

Cross-references to related applications

This application is a continuation in part of U.S. Patent Application No. 15/470,562, filed March 27, 2017, titled Integrated Systems and Methods for Evaluating Hemp and Cannabinoid Products for Public Safety, Quality Control, and Quality Assurance, which is a continuation of U.S. Patent Application No. 14 /312051, filed June 23, 2014, now published as U.S. Patent No. 9,632,069 entitled Integrated Systems and Methods for Evaluating Hemp and Cannabinoid Products for Public Safety, Quality Control, and Quality Assurance, which claims benefit and priority of U.S. Provisional Application No. 61/ 936200, filed February 5, 2014, entitled Systems and Methods for Evaluating Hemp Products for Public Safety, Quality Control, and Quality Assurance; and U.S. Provisional Patent Application No. 61/939,385, filed Feb. 13, 2014, titled Systems and Methods for Evaluating Hemp Products for Public Safety, Quality Control, and Quality Assurance, the contents of which are incorporated herein by reference in their entirety. This application also constitutes a continuation in part of an application under 35 U.S.C. § 111(a) of PCT Application No. PCT/US2018/42707, filed July 18, 2018, entitled Cannabinoid Analogue Conjugate Formulations and Methods of Use, which claims the benefit and priority of U.S. Provisional Patent Application No. 62/533894, filed July 18, 2017, entitled Compositions containing cannabinoid analogue conjugates and methods of use, the content of which is incorporated herein by reference in its entirety.

Technical field

In general, embodiments of the present invention relate to the recording and control of information on natural products such as hemp and cannabinoid products for quality control and quality assurance purposes. More specifically, embodiments of the present invention facilitate the evaluation by the supplier or consumer of a hemp and/or cannabinoid product of the efficacy, potency, quality and origin of that product. Embodiments of the present invention also relate to a hemp and cannabinoids data center where samples of these products are analyzed for public safety, quality control and quality assurance. Embodiments of the present invention also relate to testing and traceability of medical products, such as hemp and hemp products, for quality assurance, quality assurance, and therapeutic efficacy by healthcare professionals and patients.

State of the art

Hemp and cannabinoid products are legally available for human consumption for several purposes, including but not limited to medical, research and recreational purposes. Unwanted and in some cases toxic chemicals, including pesticides and plant growth regulators, are added to hemp products and threaten the health of consumers. Because some hemp products can be inhaled rather than consumed, any toxins in the products have direct access to the user's lungs and bloodstream. Some states have regulations to control the environment in which cannabis plants are grown. Most of the states where hemp products can be obtained legally do not have the means to ensure that plants grow in controlled environments. In addition to natural contamination during plant growth, hemp and cannabinoid products are unscrupulously contaminated by the use of extracts or dried parts of other plants, glass particles, industrial chemicals, sugar or sand, and other micro-pollutants. There are no reliable comprehensive systems to ensure that hemp and cannabinoid products are free of chemical and microbiological contaminants, and to track the product as the plant is grown, processed into products, and moved to stores for public consumption. Most consumers do not have access to hemp or cannabinoid products that have been tested for purity by third party accredited laboratories.

Medical cannabinoids and herbal remedies have emerged as noteworthy therapies with growing scientific evidence of therapeutic potential. However, very little work has been done to ensure the safety of developing and consuming cannabis products and assessing a direct correlation with disease outcomes. Different ways of crossing hemp seeds are used to analyze the variability in the profile of cannabinoids produced by the plant. However, the characteristics of the hemp product and their association with disease outcome have not yet been accurately traced. Changes in methodology can lead to discrepancies in the formation of the cannabinoid product, as well as other uncertainties in the offspring that cannot be initially predicted, such as an increase in the production of terpenes. Without a comprehensive way of checking/validating, medical prognosis and diagnosis may be compromised when making recommendations or prescribing cannabis for various diseases. Moreover, public safety and public trust are the main areas of policy and regulation regarding medical cannabis. Modern platforms lack an integrated approach

- 1 040867 to the control of various aspects of the industry, such as the selection of hemp seed genetics, the control of plant growth conditions, the production of products and drugs with the required safety and therapeutic profiles.

The essence of the present invention

Applicants recognize the public health and safety risks that exist when hemp or cannabinoid products are not accompanied by adequate information about their sources, production methods, contents, the results of any quality control and quality assurance procedures. Unwanted and in some cases toxic chemicals, including pesticides and plant growth regulators, are added to hemp and cannabinoid products and threaten the health and safety of consumers, so additional testing and compliance may be required prior to public consumption. Embodiments of the present invention include, for example, a hemp data center where samples of hemp and cannabinoid products are analyzed through scientific research to verify and set parameters for third parties such as government agencies for grants, public safety, quality control and quality assurance.

Exemplary embodiments of the present invention include a method for evaluating one or more hemp and cannabinoid products for use in a particular industry for research, public use, health care, or a combination thereof.

As an example, an embodiment of the present invention includes a distributed validated (authenticated) cannabis control system. An embodiment of this system includes one or more processors, an input/output unit adapted to be connected to one or more processors, one or more cannabis database connected to one or more processors for storing and correlating a plurality of regulatory guidelines. with multiple measurements of the quality and quantity of desired and undesirable components in a hemp product, one or more electronic interfaces allowing an online report to be displayed to the user and to define one or more user interfaces for hemp; and a persistent computer-readable medium for communicating with one or more processors and containing one or more computer programs stored thereon. The computer program includes a set of instructions that, when executed by one or more processors, causes the one or more processors to perform operations of generating a cannabis user interface showing its user one or more online cannabis reports, wherein the cannabis user interface provides for the input of a variety of information , associated with a user or a hemp product, determines whether a hemp product satisfies the regulation rules by obtaining a set of information related to the user or the hemp product and information from one or more cannabis databases, comparing the set of regulation rules with a set of quality measurements and the amount of desired components and undesirable components in the hemp product, and displaying on one or more hemp user interfaces one or more online hemp reports, the hemp reports including one or more of a plurality of a set of information related to the user or the hemp product, and one or more of a variety of measurements of the quality and quantity of desired components and undesirable components in a hemp product for research or for public use.

Embodiments of the present invention preferably provide, for example, sensors, distributed validated systems, computer-readable software products, and related methods for tracking hemp and cannabinoid products from seed to consumer. The technology described in the present invention is based on a blockchain transaction platform for accessing and tracking multiple transactions between various parties involved in the receipt and production of hemp products and their subsequent delivery for consumption. Any trusted person or company can access the blockchain transaction platform to verify the information associated with any of the transaction records associated with a particular product.

Embodiments of the present invention provide a distributed validated system and method for combining cannabis seed profiling and characterization (genetics/multi-mix technologies), planting/growing (cultivation), processing/manufacturing, information technology (IT)/software services, products and medicines. The embodiments described herein facilitate safe administration to subjects and also provide methods for evaluating therapeutic outcomes. Embodiments of the present invention provide methods for tracking, verifying and validating a hemp product through an integrated and comprehensive accounting and control platform, i.e. blockchain system of this product.

Embodiments of the present invention provide a method for recording and controlling hemp product related information over a distributed validated system. The method includes ensuring that a first authorized user creates a first data set containing a genetic profile of seeds used in obtaining a hemp product. The method includes matching the first set of data to the first record, which is identified by the first unique identifier. The method includes storing a first entry in memory for access by one or multiple authorized users using a first unique identifier. The method includes causing the second authorized user to create a second data set containing the growing conditions of the crop used in the production of the hemp product. The method includes matching the second set of data to a second record that is identified by a second unique identifier. The method includes storing a second entry in memory for access by one or more of a plurality of authorized users using a second unique identifier. The method includes causing a third authorized user to create a third data set containing information about the manufacture of a hemp product. The method includes matching a third data set with a third record that is identified by a third unique identifier. The method includes storing a third entry in memory for access by one or more of a plurality of authorized users using a third unique identifier. The method includes analyzing a hemp product, determining the quality and quantity of desired components and undesirable components in a hemp product, applying one or more of cannabinoid profiling, microbiological testing, analytical testing, food testing, acidified food testing, fluid testing, pathogens, quality control and quality assurance. The method includes determining the concentration of one or more cannabinoids in a hemp product. The method includes ensuring that a fourth authorized user creates a fourth data set containing quality and quantity indicators of desired components and undesirable components in a hemp product. The method includes matching a fourth data set with a fourth record that is identified by a fourth unique identifier. The method includes storing a fourth entry in memory for access by one or more of a plurality of authorized users using a fourth unique identifier.

In some embodiments, each of the first identifier, the second identifier, the third identifier, and the fourth identifier provide access to one or more of the first data set, the second data set, the third data set, and the fourth data set. In some embodiments, each of the first entry, second entry, third entry, and fourth entry includes a timestamp. In some embodiments, each of the first write stage save, the second write stage save, the third write stage save, and the fourth write stage save are each verified by one or more of a plurality of authorized users. In some embodiments, the first data set further includes data selected from the group consisting of seed purchase claim data, grower data, breeder data, seed purchase data, and combinations thereof. In some embodiments, the second set of data includes data selected from the group consisting of seed planting data, soil data, weather data, water content data, moisture data, pressure data, light data, temperature data. nutrients, pesticide data, microorganism data, toxicant data, crop growing data, harvest data, storage data, and combinations thereof. In some embodiments, the third data set includes data selected from the group consisting of supplier data, distribution data, extraction data, purification data, and combinations thereof. In some embodiments, the method further includes the step of comparing the quality and quantity of desired components and undesirable components in one or more hemp products and the concentration of one or more cannabinoids with the corresponding regulatory requirements for the consumption of a hemp product. The method further includes the step of certifying that the hemp products meet or do not meet relevant regulatory requirements. In some embodiments, the method further includes the step of causing the fourth authorized user to create a fourth data set containing the dose and dosage of the hemp product provided to the consumer. The method further includes the step of matching the fifth data set with the fifth record, which is identified by the fifth unique identifier. The method further includes the step of storing the fifth entry in memory for access by one or more of the plurality of authorized users using the fifth unique identifier. In some embodiments, the fifth identifier provides access to one or more of the first data set, the second data set, the third data set, the fourth data set, and the fifth data set. In some embodiments, the implementation of the fifth entry includes a timestamp. In some embodiments, the fifth data set includes data selected from the group consisting of physician data, pharmacist data, patient data, consumer data, imaging data, treatment data, treatment outcome data, and combinations thereof.

- 3 040867

Embodiments of the present invention provide a method for recording and controlling information related to a hemp product over a distributed validated system. The method includes obtaining a sample of a hemp product. The method includes testing a sample for one or more of moisture content, microbial/pathogenic/mycotoxin profile, pesticide and toxic profile, residual solvents, heavy metal content, terpene profile, and cannabinoid profile. The method includes ensuring that an authorized user creates a set of data containing the parameters obtained during the testing phase. The method includes associating a set of data with a record that is identified by a unique identifier. The method includes storing an entry in memory for access by one or multiple authorized users using a unique identifier. In some embodiments, the method further includes the step of storing the hemp product for a predetermined period of time.

Brief description of the drawings

In order that the manner in which the features and advantages of the present invention, as well as other parameters, become apparent could be made clear in more detail, a more specific description of the embodiments of the present invention may be made by reference to its embodiments, which are illustrated by the accompanying drawings. which form part of this description. However, it should also be noted that the drawings only illustrate various embodiments of the present invention and, therefore, should not be considered as limiting the scope of the present invention, as it may also include other effective embodiments.

Fig. 1 is a block diagram of an exemplary method according to one embodiment.

Fig. 2 is a block diagram of an exemplary method according to one embodiment.

Fig. 3 is a schematic representation of an exemplary system according to one embodiment.

Fig. 4 is a block diagram of an exemplary system according to one embodiment.

Fig. 5 is a block diagram of an exemplary method according to one embodiment.

Fig. 6 is a block diagram of an exemplary method according to one embodiment.

Detailed description

The present invention will now be described in more detail with reference to the accompanying drawings, which illustrate various embodiments of the present invention. However, the present invention may be practiced in many different ways and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that the present invention is complete and complete, and fully conveys the scope of the present invention to a person skilled in the art. It should be fully recognized that the various ideas of the various embodiments discussed below can be applied alone or in any suitable combination to obtain the desired results. The various characteristics above, as well as other features and characteristics described in more detail below, will be readily apparent to one skilled in the art upon reading the following detailed description of the various embodiments, and referring to the accompanying drawings. In the drawings and in the description that follows, like parts are designated in the description and in the drawings by the same reference numerals, respectively. Some structural features of the present invention may be shown on an enlarged scale or in somewhat schematic form, and some details of conventional elements may be omitted in the interests of clarity and brevity.

The present invention may use phrases in some embodiments, in different embodiments, in a particular embodiment, or in embodiments, each of which may refer to one or more of the same or different embodiments. Moreover, the terms containing, including, having, and the like, as used in relation to embodiments of the present invention, are synonymous.

Exemplary embodiments of the present invention preferably provide, for example, sensors, systems, computer-readable software products, and related methods for tracking hemp and cannabinoid products from seed to consumer. The technology described in the present invention is based on a blockchain transaction platform for accessing and tracking multiple transactions between various parties involved in the manufacture and receipt of hemp products and their subsequent delivery for consumption. Any fiduciary or company

- 4 040867 may have access to the blockchain transaction platform to verify the information associated with any of the transaction records associated with a particular product.

As used in the present invention, the term blockchain (chain of blocks) refers to a time-dependent growing list of immutable information objects or records (hereinafter referred to as blocks in the present invention) that are linked by cryptography. As used in the present invention, the term timestamp refers to a sequence of digits or encoded information that specifies when a particular event has occurred. The timestamp includes digital data and time information that can be attached to the block. As used in the present invention, the terms hash or hash value refers to a value resulting from a hash function, which is a function used to map certain data of arbitrary size to finite size data. A hash is a unique identifier associated with a block and is a key element of the distributed validation system described in the present invention. Typically, each block is associated with a timestamp, a hash of the current block, and a hash associated with the immediately last block of the current block.

Seed, as used in the present invention, refers to a reproduction unit of a plant of the genus Cannabis capable of developing into another given plant.

The term is used in the present invention to include both the seed, which is produced by sexual reproduction, and the cutting or clone, which is a unit of asexual reproduction. As used herein, a hemp product or cannabinoid product includes, but is not limited to, any applicable product legally intended for research or human consumption and containing one or more of Δ-9tetrahydrocannabinol, 8-tetrahydrocannabinol, cannabichromene, cannabicyclol, cannabidiol, cannabielzoin, cannabigerol, cannabinidiol, cannabinol, cannabitriol and cannabidiolic acid. Hemp products may contain two or more of these cannabinoids in varying proportions. Hemp products may include products that are infused with one or more of the above cannabinoids and are intended for legal human consumption. Hemp products may include products derived from natural or genetically modified plants that are scientifically defined as Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Hemp products may include laboratory-produced products containing one or more of Δ-9-tetrahydrocannabinol, 8-tetrahydrocannabinol, cannabichromene, cannabicyclol, cannabidiol, cannabielzoin, cannabigerol, cannabinidiol, cannabinol, cannabitriol, cannabidiolic acid, nabilone, and endocannabinoids such as 2-arachidonoylglycerol, n-arachidonoyldopamine, virodhamine, and noladin ester. A hemp product may include products that have been processed to contain one or more of the sixty different cannabinoids found in hemp samples derived from natural or genetically modified plants that are scientifically identified as Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Embodiments of the present invention also include testing cannabinoid products that are isolated from hemp and documenting the information in a block. Accordingly, a hemp product as used in the present invention further includes products that contain one or more hemp-derived cannabinoids. Hemp products can take a number of forms, including: dried plant, resin, powdered form, oil, smoked products, vaporized products, and cannabis-infused teas, candies, cookies, and cakes. Hemp products may contain hemp compounds, derived from natural sources or otherwise, and incorporated together with organic or inorganic components, including, but not limited to, natural, polar or non-polar solvents. Hemp products can be used for medicinal, research, recreational purposes, or a combination of both.

A hemp product or cannabinoid product includes, but is not limited to, cannabinoid analogues. As used in the present invention, the term cannabinoid analog refers to a compound capable of either interacting with cannabinoid receptors in a subject or possessing chemical similarity to cannabinoids, or both. Cannabinoid analogues include synthetic or natural cannabinoid compounds that function as agonists or antagonists. Embodiments of cannabinoid analogs include, but are not limited to, cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidiol monomethyl ester (CBDM), cannabidiol- _C4 (CBD-C4), cannabidivarinic acid (CBDA), cannabidivarine (CBV) , cannabidiorcol (CBD-C ₁ ), tetrahydrocannabinol (THC), N-arachidonoylethanolamine (AEA) or anandamide, 2-arachidonoylglycerol (2-AG), rimonabant, AM6538, taranabant, otenabant, cannabigerolic acid monomethyl ester (CBGAM), monomethyl ether cannabigerol (CBGM), cannabigerovarin (CBGV), cannabigerovarin acid (CBGVA), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromevarin acid CBCVA), cannabichromevarin (CBCV), Δ-9-5 040867 tetrahydrocannabinolic acid A (THCA-A) ), Δ-9-tetrahydrocannabinolic acid B (THCA-B), Δ-9-tetrahydrocannabidiol (THC), Δ-9-tetrahydrocannabinolic acid-C ₄ (THC-C ₄ ), Δ-9tetrahydrocannabivarinic acid (THCVA), Δ- 9-tetrahydrocannabivarin (THCV), Δ-9tetrahydroca nnabiorcolic acid (THCA-C ₁ ), Δ-9-tetrahydrocannabiorcol (THC-C ₁ ), A-7-cisisotetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinolic acid (Δ-8-THCA), Δ-8-tetrahydrocannabidiol (Δ- 8-THC), cannabicyclolic acid (CBLA), cannabicyclol (CBL), cannabicyclovarin (CBLV), cannabielsoyic acid A (CBEA-A), cannabielsoyic acid B (CBEA-A), cannabielsoiin (CBEA-A), cannabinolic acid (CBNA ), cannabinol (CBN), cannabinol methyl ester (CBNM), cannabinol-C ₄ (CBN-C4), cannabinol-C2 (CBN-C ₂ ), cannabiorcol (CBN-C ₁ ), cannabinodiol (CBND), cannabinodivarin (CBVD ), cannabitriol (CBT), 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol, 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol, cannabitriolvarin (CBTV) and ethoxy-cannabitriolvarin (CBTVE).

A hemp product or cannabinoid product includes, but is not limited to, therapeutic and diagnostic compositions containing a label-complexing-medical cannabinoid analogue conjugate. The labels may be radionuclides that are used to label the medical cannabinoid analogue through a complexing agent. Certain embodiments include cycles (N ₄ ) as a complexing agent. As used in the present invention, the term diagnostic and therapeutic refers to agents or uses that function as either diagnostic or therapeutic methods.

As used in the present invention, the term complexing agents refer to compounds that form coordination complexes when bound to metal ions or other substrates. The structure of the chelate ligands and the metals that chelate with them may vary depending on the desired application. Many ligands that bind to radioactive metals are tetradentate and contain a combination of four metal-coordinating nitrogen and/or sulfur atoms (ie N ₄ , N ₃ S, N2S2 and the like). Example of complexing agents that can be used in the present invention include cyclam compounds (N4), diethylenetriaminepentaacetic acid (OTPA), tetraazacyclododecane-N,N',N,N'-tetraacetic acid (DOTA), ethylenediaminetetraacetic acid (EDTA), dimercaptosuccinic acid (DMSA), sulfuric colloid and N ₂ S ₂ systems such as MAMA (monoamide monoamine dithiols), DADS (N ₂ S ₂ diamindithiols), CODADS and the like. These complexing systems and a number of others are described in Liu and Edwards, Chem Rev. 1999, 99 (9), 2235-2268; N2S2 is also described in US Pat. Nos. 4,897,225; 5164176; or 5,120,526. A method for making certain N ₄ compounds is described in US Pat. No. 5,880,281, but they can also be obtained from commercial sources such as Sigma Aldrich Chemical (Milwaukee, Wis.) and TCI America (Portland, OR). Some N ₄ compounds that can be used as complexing agents may include, but are not limited to, 1,4,7,10-tetraazacyclododecane (cyclene), 1,4,7,10-tetraazacyclotridecane (cycle 13), 1, 4,7,11-tetraazacyclotetradecane (isocyclam), 1,5,9,13tetraazacyclohexadecane, 1,5,9,13-tetraazacycloheptadecane, 1,5,9,14-tetraazacyclooctadecane, 1,5,10,14tetraazacyclooctadecane, 1.5 ,10,15-Tetraazacyclodonodecan, as described in US Pat. No. 8,758,723, 6,093,382; 5608110; 5665329; 5688487, US Patent Publication No. 2012/0276005 and PCT/GB 2005/002807. Other examples of complexing moieties include, but are not limited to, tetraazacyclododecane-N,N',N,N'-tetraacetic acid monoamide, (DOTA-MA); 10-(2hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A). The N ₄ is conjugated to a medical cannabinoid compound and then complexed with a metal. N ₄ has a cyclic structure, which contributes to the stabilization of radionuclides. Higher lipophilic complexing agents such as N4 also confer reduced renal and hepatic toxicity as they showed reduced accumulation in these organs resulting from greater uptake by the target cells. Conjugation of DOTA with the highly selective CB2 receptor inverse agonist SR144528, followed by chelation with gallium (Ga), technetium (Tc), copper (Cu), or lanthanides such as gadolinium (Gd), europium (Er), terbium (Tb), is described in US Pat. No. 8,367,714. Imaging of the CB1 receptor using various radioactive tracers is described in PCT/US 2009/043491. Radioligands with high affinity and selectivity for CBi receptors, such as 3,4-diarylpyrazoline derivatives, are labeled with a radioisotope selected from the group consisting of ² H, ^{14 C} , 13 N, ¹⁸ F, ⁷⁵ Br, ⁷⁶ Br, and ¹²³ I for imaging. PET or SPECT. US Patent Nos. 8840865, 9617215, 8323621, US Patent Publication 2005/0070596 and WO 2007130361 describe the imaging of the cannabinoid system for medical and therapeutic purposes for the treatment of, for example, inflammatory diseases, cancer, neurological disorders.

As used in the present invention, the term label refers to an atom, molecule or compound that is used to determine the position of the composition to which the label is attached. Labels may have one or more of fluorescent, phosphorescent, luminescent, electroluminescent, chemiluminescent, or other spectroscopic properties. These properties make it possible to detect and identify label-complexing-medical conjugates.

- 6 040867 cannabinoid analogue, using any method capable of detecting and identifying the label, including spectroscopy in the visible region of the spectrum, ultraviolet and infrared spectroscopy, Raman spectroscopy, nuclear magnetic resonance, positron emission tomography and other methods known in the art.

As used herein, the term imaging refers to all tissue imaging techniques using electromagnetic wave techniques for which the present compositions can be applied, including, but not limited to, nervous system cells, blood cells, cancer cells, and precancerous cells. The present invention relates to neuronal imaging kits. In one embodiment, the kit contains a predetermined amount of a complexing agent conjugate and a medical cannabinoid analogue; and a predetermined amount of imaging agent. The conjugate of the complexing agent and the medical cannabinoid analog may be present in the kit as precursors which are then reacted with the imaging agent, provided suitable reaction conditions are provided. The kit may also contain a reducing agent containing tin. The present invention also includes kits for genomic or other omics assays that contain a predetermined amount of a complexing agent conjugate and a medical cannabinoid analogue; and a predetermined amount of imaging agent.

As used in the present invention, the terms radionuclide, radioactive nuclide, radioisotope or radioactive isotope are synonymous. One or more different radioisotopes can be used as labels. Non-limiting examples of radionuclides include ^99m Tc, ^117m Sn, ^{177 Lu} , ¹⁸⁸ Re, 186 Re, ¹⁵³ Sm, ¹⁶⁶ Ho, ⁹⁰ Y, ⁸⁹ Sr, ⁶⁷ Ga, ⁶⁸ Ga, ⁿ¹ In, ¹⁸³ Gd, ⁵⁹ Fe, ²²⁵ Ac , ²¹² Bi, ²¹¹ At, ⁴⁵ Ti, ⁶⁰ Cu, ⁶¹ Cu, ⁶⁷ Cu, ⁶⁴ Cu and ⁶² Cu. In other aspects, the metal ion is a non-radioactive metal such as ¹⁸⁷ Re, ⁶⁹ Ga and ¹⁹³ Pt.

The hemp product that is evaluated in the embodiments of the present invention can be obtained from a number of sources, including, but not limited to, growers, farmers, hemp product manufacturers and processors, and hemp product wholesalers and retailers. As used herein, growers include an individual or person authorized by a state or federal control board or agency to grow, plant, cultivate, harvest, or similarly engage in the production of natural or genetically modified plants that are scientifically defined as Cannabis sativa, Cannabis indica and Cannabis ruderalis. Producers also include an individual or person authorized by a state or federal control board or agency to purchase raw materials and chemically obtain or similarly participate in the production of hemp products.

As used in the present invention, a hemp product processor may include, but is not limited to, an individual or a person authorized by a state or federal control board or agency to process natural or chemical raw materials, obtain hemp products, package and label hemp products for sale in retail stores. outlets, as well as sell hemp products to wholesalers and retailers.

As used herein, a retailer of a hemp product may include, but is not limited to, an individual or a person authorized by a state or federal control board or agency to sell hemp products at retail outlets. As used herein, a retail outlet may include, but is not limited to, a location authorized by a state or federal control board or agency to retail hemp products. For example, without limitation, Federal agencies such as the USDA, the Food and Drug Administration, and the Drug Enforcement Agency may regulate the consumption of hemp products and provide necessary guidelines for testing hemp products. For example, without limitation, Washington state retailers include organizations that sell hemp products under license from the Washington Liquor Control Board. For example, without limitation, retailers in the state of Colorado include organizations that sell cannabis products under license from the Marijuana Enforcement Administration.

As used in the present invention, users may include, but are not limited to, individuals and persons who use or benefit from certain embodiments of the present invention, receiving information related to hemp products. Consumers may also include plant growers, manufacturers and distributors of hemp products, researchers or healthcare professionals in public and private institutions, and wholesalers and retailers of hemp products. Users also include individuals and individuals who legally obtain hemp products from plant growers, hemp product manufacturers and distributors, and hemp product wholesalers and retailers. Users also include, but are not limited to,

- 7 040867 people who consume a hemp product for medical or recreational purposes, or for any legally approved reason. Users also include, but are not limited to, individuals who are employees or agents of government agencies (such as researchers who may conduct research for human and non-human applications) and have a legitimate reason to access information related to hemp products. As used in the present invention, the term subject refers to all animal species, including humans, rodents, other mammals, or bird species. Cannabinoid-based compositions can serve as a diagnostic agent, prognostic agent, or agent that alleviates or treats a disease in a subject. The target site can be any tissue in the subject, including but not limited to the brain, heart, lung, esophagus, intestines, breast, uterus, ovary, prostate, testis, stomach, bladder, or liver. In addition, embodiments of the present invention can be used as agents targeting diseases such as cancer or neurological, gastrointestinal, metabolic and neuroendocrine diseases. As used in the present invention, the term administration refers to the activity of administering the composition described in the present invention to a subject by a suitable route, and the composition can be administered by various routes of intravenous, oral, intramuscular, transdermal, intraperitoneal, topical, sublingual, buccal, inhalation, nasal or ophthalmic methods if they can deliver it to the target tissues. The compositions described in the present invention can be delivered as a pharmaceutical formulation.

As used in the present invention, users may include, but are not limited to, individuals and individuals who are involved in the preparation and use of specific hemp products for personalized medicine. For example, these specific hemp products include therapeutic and diagnostic compositions that target the endocannabinoid system (ECS) involved in the pathogenesis of neurological disorders and cancer. This personalized medical platform enables the delivery of personalized medicines based on the individual genetic profile, biochemistry, molecular imaging, molecular design, and clinical observations and measurements associated with each patient's disease. In another example, these specific hemp products are part of compositions for imaging or treating diseased cells. Certain compositions contain a cannabinoid analog and a chemotherapeutic agent. Certain compositions contain a chemotherapeutic agent and a cannabinoid analog conjugated to a complexing agent. In certain embodiments, the complexing agent is a cycle. In certain embodiments, the cannabinoid analog is cannabidiol. Certain embodiments include compositions containing a combination of a chemotherapeutic agent and a cannabinoid analog conjugated to a complexing agent and a label. In certain embodiments, the chemotherapeutic agent is Bruton's tyrosine kinase inhibitors such as ibrutinib (IBN) and zanubrutinib (BGB). In certain embodiments, the chemotherapeutic agent is a proteasome inhibitor such as carfilzomib (CFZ). In certain embodiments, the chemotherapeutic agent is Tumorex (TMX).

Information relating to hemp products includes any or all of the information related to the origin, efficacy, potency, quality and quantity of required components and undesirable components in hemp products, government licenses and approvals for hemp products, therapeutic results after administration or consumption of these products or any combination of this information. Desired components in hemp products include, without limitation, chemical components and biological components of the hemp product that ensure that the hemp product meets the requirements for sale or consumption by people in a particular industry. Desired components include, for example, without limitation, cannabinoids, pharmaceutically acceptable salts, pharmaceutical excipients, flavors, and food colorings. Undesirable components in hemp products may include, without limitation, chemical components and biological components of the hemp product that render the hemp product unsalable in a particular industry. Undesirable components include, for example, without limitation, pathogens and toxic substances such as pesticides, fertilizers, and plant growth regulators. Desired components in a hemp product in a particular industry may represent undesirable components in another industry. As used in the present invention, the term pharmaceutically acceptable salt refers to salts that retain the biological efficacy and properties of the parent compound and, unless otherwise indicated, a pharmaceutically acceptable salt includes salts of acidic or basic groups that may be present in the compounds of the formulas described in the present invention. Certain hemp products include conjugates of a complexing agent and a targeting ligand. These products can be used for imaging, diagnostic and/or therapeutic purposes.

- 8 040867

In certain embodiments, the hemp product being monitored by a distributed validated cannabis monitoring system is a pharmaceutical formulation. A pharmaceutical composition refers to a mixture of one or more compounds described in the present invention or a pharmaceutically acceptable derivative as an active ingredient and at least one pharmaceutically acceptable carrier or excipient. The purpose of a pharmaceutical composition is to facilitate the administration of a compound to a subject. In another aspect, the pharmaceutical composition may contain a compound of one of the formulas described in the present invention, or a pharmaceutically acceptable derivative and a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition contains two or more pharmaceutically acceptable salts, acids, esters, excipients, carriers, diluents, and combinations thereof. The term pharmaceutically acceptable derivative, as used herein, refers to and includes any pharmaceutically acceptable salt, prodrug, metabolite, ester, ester, hydrate, polymorph, solvate, complex, and adduct of a compound described herein which, when administration to a subject is able to provide (directly or indirectly) the active ingredients. For example, the term pharmaceutically acceptable derivative of the compounds described in the present invention includes all derivatives of the compounds described in the present invention (such as salts, prodrugs, metabolites, esters, esters, hydrates, polymorphs, solvates, complexes, and compound addition products) which, when administered to a subject, are capable of providing (directly or indirectly) the compounds described in the present invention.

For example, cannabis products tracked through a distributed validated cannabis control system include cannabinoid-based compositions used to visualize diseased cells. These compositions can be used in the diagnosis, evaluation and treatment of any disease, and information associated with the subjects receiving these compositions is also an input to a distributed validated cannabis control system. The disease can include any form of nervous disorders and cancer. In particular, the cancer may include one or more of the carcinoid types of cancer, neuroendocrine cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, kidney cancer, skin cancer, head and neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, colorectal cancer, and hematopoietic cancer such as lymphoma or leukemia. Neurological conditions may include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis, post-traumatic stress disorder (PTSD), epilepsy, seizures, Tourette's syndrome, schizophrenia, anxiety disorders, autism, depression, dementia, and other diseases and disorders that affect the nervous system.

A distributed validated cannabis control system may include blocks from users of imaging modalities using these cannabis products, and containing information such as sensitivity and specificity, problems with patient administration, and side effects. Other information may also include time and cost data associated with any of the above. Healthcare professionals may have access to blocks of information to track the specific cannabis product that was administered to the subject. Healthcare professionals may also enter and access information related to the diagnosis, prognosis, and treatment of a patient, especially when the patient is being treated or treated with medical cannabinoids. Certain embodiments include methods of imaging at the site of a disease in a specified subject to assess before or after treatment and to be able to track the subject for as long as the subject is in treatment or in the treatment of medical cannabinoids. In certain embodiments, the diagnostic laboratory systems may provide information to a distributed validated cannabis monitoring system. Accordingly, any imaging technique can be used to detect signals from one or more labels. Non-limiting examples of imaging methods used to detect signals from labels include PET, PET/CT, CT, SPECT, SPECT/CT, MRI, near infrared (NIR), optical imaging, optoacoustic imaging, and ultrasound.

The Cannabis Distributed Validated Control System also includes blocks from kit manufacturers that contain imaging probes, a diagnostic agent, or a pharmaceutical composition. Certain specific embodiments include building blocks of systems involved in imaging, testing, diagnosing, or delivering a hemp-based composition for the treatment of physiological disorders. Authorized users of the Distributed Validated Cannabis Control System may access and provide input regarding personalized and effective dose and dosing regimens involving the use of medical cannabinoids.

The distributed validated cannabis control system also includes blocks from manufacturers, suppliers and distributors of cannabinoid-based compositions such as conjugates

- 9 040867 label-complexing agent-medical cannabinoid analogue. These conjugates may contain phytocannabinoids, which are naturally occurring plant cannabinoids. Manufacturers, suppliers and distributors of medical cannabinoids are involved in the production, extraction, purification and distribution of these natural compounds that are isolated from plants. Cannabinoid-based compositions also include label-complexing-terpenoid analog conjugates, label-complexing-flavonoid conjugates, and label-complexing-phytosterol conjugates. Among natural medical phytocannabinoids, Δ-9tetrahydrocannabinol (Δ-9-THC), cannabidiol (CBD) and cannabinol (CBN) are the most abundant, with other phytocannabinoids playing a very important role in personalized medicine. Based on structure, binding properties, and signaling/functional features, medical cannabinoids are grouped into different classes:

(i) classic medical cannabinoids, which include both natural plant extracts such as Δ-9-THC and chemically synthesized compounds such as marinol;

(ii) non-classical medical cannabinoids, mainly represented by the synthetic cannabinoid receptor (CB) agonist CP-55,940;

(iii) aminoalkylindoles, which include chemically derived cannabinoids such as AM1241;

(iv) diarylopyrazoles, which include CB inverse agonists (or antagonists) such as SR141716A, also known as rimonabant; and (v) endogenous endocannabinoids, which are naturally synthesized by animal and human cells and include N-arachidonoylethanolamine, (AEA) or anandamide, 2-arachidonoylglycerol (2-AG), noladin ester, virodchamin, and N-arachidonyl dopamine (NADA).

Examples of the label-complexing-medical cannabinoid analog conjugate include medical cannabinoids such as dronabinol, nabilone, nabiximols, cannador, cannabidiol, cannabinol, cannabigerol, tetrahydrocannabivarin, and cannabichromene. Examples of the label-complexing-medical cannabinoid analogue conjugate include medical cannabinoids such as HU-210, A-9-THC, Δ-8-THC and deacetyl-L-natradol, which are known as CB1/ _CB2 receptor agonists without a distinctive specificity for both receptors. Δ-9-THC is isolated as a C. sativa cannabinoid that exhibits CB1/CB2 affinity and the highest psychotropic effects. Substitution of pentyl in the Δ-8-THC side chain converts to a HU-210 analog with increased receptor affinity. Other structural modifications of the THC backbone lead to new and selective CB ₂ agonists JWH-133, JWH-139 and HU-308 and L-759633 and L-759656, which show affinities in the nanomolar range. Examples of the label-complexing-medical cannabinoid analogue conjugate include the non-classical medical cannabinoids, which are a family of bicyclic (AC) and tricyclic ACD medical cannabinoids. They are significantly represented by CP55940, along with CP55244 and CP47497 counterparts. Of note, CP55940 is the best-known medical cannabinoid agonist that exhibits potent in vivo effects through generalized CB1 and CB2 signaling. Examples of the tag complexing agent-medical cannabinoid analog conjugate include aminoalkylindoles. R(+)-WIN55212 is a prototype of this family with properties similar to medical cannabinoids that can bind to both CB1 and CB2 receptors, but exhibits greater specificity for CB2 and can mimic THC-mediated effects in vivo. Other analogues like JWH-015 and L-768242 also show similar affinity to CB2 as R-(+)-WIN55212. Examples of the label-complexing-medical cannabinoid analog conjugate include the medical diarylpyrazoles, which are a class of medical cannabinoid analogs whose distinctive function is to inhibit CB1 or _CB2 dependent intracellular signaling pathways by acting as antagonists (inverse agonists); for example, embodiments include SR141716A, AM251, and AM281, which inhibit effects mediated by the CB1 receptor. Examples of the tag-complexing-medical cannabinoid analog conjugate may include certain endocannabinoids. N-arachidonoylethanolamine (AEA) or anandamide, is an example of an eicosanoid that is converted to its active form via the omega-3 (ω-3) and omega-6 (ω-6) fatty acid biosynthetic pathways, and specifically targets CB receptors in mammals. In this regard, other eicosanoids that may function in these embodiments include methanandamide (R and S isomers), arachidonyl-2-chloroethylamide (ACEA), arachidonylcyclopropylamide (ACPA), and 2-arachidonoylglycerol (2-AG), which show binding affinity for CB1 and CB2.

The Distributed Validated Cannabis Control System also includes blocks of systems used by consumers, patients, and healthcare professionals who use cannabinoid-based medical compositions as therapeutic and diagnostic agents targeting serious pathologies such as cardiovascular, neurological, psychiatric, immunological, endocrine and neoplastic diseases. For example, authorized users

- 10 040867 distributed validated cannabis control system can access and enter information related to the impact of medical compositions based on cannabinoids on health and disease and early success or failure for specific applications. In a specific example, authorized users of a distributed validated cannabis control system may access and enter information related to the effect of a particular medical cannabinoid analogue in the treatment of chronic pain.

For example, authorized users of a distributed validated cannabis control system can access and enter information related to the ECS and other pathways that modulate parallel functions aimed at protecting and maintaining a subject's homeostasis. CB1 is mainly expressed in the central and peripheral nervous system, but a discrete distribution is observed in other tissues. Thus, the use of label-complexing-medical cannabinoid analog conjugates targeting CB1 signaling may result in a broad and pleiotropic effect. Although the CB1 receptor is known to primarily regulate functions related to cognition, memory, perception, mood, behavior, and psychotropic activity, there is growing evidence that it may play a role in pain management, cardiovascular, respiratory, and reproductive health. functions, as well as in maintaining general homeostasis. CB2 receptors are predominantly expressed in immunocompetent organs, where cells undergo antigen-dependent maturation and selection programs, enabling them to evaluate and mount potent responses against pathogens and developmental disorders. CB2 shows a relatively limited distribution in the central nervous system (CNS). CB ₂ -dependent activation includes regulatory mechanisms that support the migration of immune cells to the site of inflammation and the release of cytokines. Expression of CB2 is especially important for CNS microglia, as shown by the ability of medical cannabinoid agents to reduce cytokine-mediated neuroinflammation. Embodiments of a label-complexing medical cannabinoid analog conjugate that include specific CB2 ligands such as O-3223 (a synthetic CB2 specific agonist) can be used for anti-inflammatory and antinociceptive applications without apparent CB ₁ -like mediated effects.

For example, authorized users of a distributed validated cannabis control system can access and enter information related to the manufacture, distribution, provision, administration and use of compositions containing label-terpenoid complexing conjugates, and enter information on antioxidant, anti-inflammatory, analgesic, antitumor, antibiotic into the blockchain. and antipsychiatric (anxiety and depression) beneficial properties of terpenoid compounds. For example, authorized users of a distributed validated cannabis control system can access and enter information related to the manufacture, distribution, provision, administration and use of compositions containing tag-complexing-flavonoid conjugates and enter information on the antioxidant, anti-inflammatory and anti-tumor properties of flavonoids into the blockchain. compounds, including hemp polyphenolic flavonoids. Hemp flavonoids may provide significant cardiovascular protection, in particular improving coronary circulation by maintaining homeostatic blood pressure, preventing blood clots, and reducing the risk of atherosclerosis. The mechanisms of antioxidant and anti-inflammatory effects mediated by hemp flavonoids include epigenin (4',5,7-trihydroxyflavone) dependent TNF-α inhibition, which has also been shown to have therapeutic effects in multiple sclerosis and rheumatoid arthritis. For example, authorized users of a distributed validated cannabis control system can access and enter information related to the manufacture, distribution, provision, administration and use of compositions containing label-chelator-phytosterol conjugates and enter into the blockchain information on cardiovascular protection, anti-inflammatory and decongestant properties. phytosterol compounds, including medical hemp phytosterols. In another example, authorized users of a distributed validated cannabis control system can access and enter information related to the manufacture, distribution, provision, administration, and use of compositions containing synthetic antagonists such as taranabant, otenabant, and AM6538, as well as the inverse agonist/antagonist rimonabant. .

In certain embodiments, a hemp product derived from any one or more of the sources described above may be subjected to a series of research or public use test protocols that determine the quality and quantities of required components and undesirable components. The supplier, researcher, healthcare professional or consumer of one or more hemp products can evaluate the origin, efficacy, potency and quality of one or more hemp products by evaluating information obtained from other participants in the supply chain or as obtained by various testing protocols. The amount of required components and undesirable components in a hemp product can be expressed in terms of absolute weight, absolute volume or relative weight or relative volume compared to other

- 11 040867 chemical components in a hemp product. Test protocols may include one or more analytical tests and methods for separating, identifying, and quantifying chemical components. For example, without limitation, a hemp product may be subjected to a battery of routine assays or specialized studies. Testing protocols may include, without limitation, one or more of the following: microbiological testing, analytical testing, food testing, acidified food testing, fluid testing, pathogen testing, quality control, quality assurance, additional testing, or combinations thereof. . Analytical testing, for example, but not limited to, may include extractable/leachate studies, characterization of reference samples, structural analysis of target/leader compounds, structural analysis of unknown substances, impurities and degradation products, identification and characterization of quantities of chemical components, synthesis and purification from impurities and degradation products, and elemental analysis of hemp products. Analytical tests, for example, without limitation, may include tests establishing the cannabinoid profile and the potency and potency of the cannabinoids present, tests determining the dose delivered by a particular formulation or food product, and tests to obtain products with an appropriate dose. A cannabinoid profile involves the identification and quantification of at least the main cannabinoids found in a hemp product. For example, in certain embodiments, determining the amount of desired components in a hemp product includes determining the concentration of one or more cannabinoids in one or more of the hemp products. For example, in certain embodiments, the amount of required components, such as tetrahydrocannabinol (THC), along with other cannabinoids and terpenoids, can be determined by either liquid chromatography or mass spectrometry, or both. This is especially important for food forms of hemp products, where a greater percentage of the active ingredients reach the bloodstream. An appropriate dosage may provide a medical or health benefit to the consumer, while an excessive or inappropriate dosage may have deleterious side effects.

As used in the present invention, microbiological testing may include, but is not limited to, testing protocols that determine, for example, the presence of microorganisms, the type of microorganisms, the number, or combinations thereof. Examples of microbiological testing include total bacteria, total aerobic bacteria, total anaerobic bacteria, psychotrophic plate counts, probiotic, genomic, proteomic, and multiomic tests. Examples of undesirable microorganisms include, without limitation, E. coli, E. coli, lactic acid bacteria, mesophilic spore formers, molds, yeasts, and thermophilic spore formers.

As used in the present invention, food testing may include, but is not limited to, food industry testing protocols that determine the qualities and quantities of required components and undesirable components, for example, without limitation, the presence of microorganisms, the type of microorganisms, the amount, or combinations thereof. . Examples of food testing include total bacteria, total aerobic bacteria, total anaerobic bacteria, psychotrophic plate counts, probiotic, genomic, proteomic, and multiomic testing. Examples of undesirable microorganisms include, without limitation, E. coli, E. coli, salmonella, Staphylococcus aureus, and fungi such as yeasts and molds.

As used in the present invention, fluid testing may include, but is not limited to, testing protocols that test fluids containing hemp products, determining the quality and quantity of required components and undesirable components. For example, without limitation, a hemp product in liquid form can be tested for the presence of microorganisms, type of microorganisms, amount, or combinations thereof. Examples of fluid testing include total bacteria, total aerobic bacteria, total anaerobic bacteria, psychotrophic plate counts, probiotic, genomic, proteomic, and multiomic tests. Examples of undesirable microorganisms include, without limitation, E. coli, including fecal E. coli, E. coli, Salmonella, Staphylococcus aureus, and fungi such as yeasts and molds. Certain embodiments of the present invention include testing protocols for determining the presence and number of pathogens, such as, but not limited to, Bacillus cereus, Campy lobacter, Chronobacter, Clostridium perfringens, Hemorrhagic E. coli (O157:H7), Listeria monocytogenes, Non-0157 STEC E.coli, Salmonella, Staphylococcus aureus, Shigella, Vibrio and Yersinia.

In certain embodiments of the present invention, a hemp product derived from any one or more of the sources described above may be subjected to a range of testing protocols that determine compliance with federal and state agency and board regulations, including, but not limited to, labeling, packaging, mixing, administration to the patient or implementation, or a combination thereof. For example, without limitation, federal

- 12 040867 Agencies that regulate food labeling include the FDA and USDA. Examples of regulations also include, without limitation, guidelines related to labelling, nutritional claims, monitoring and evaluation of hemp products, or a combination thereof. Another embodiment of the present invention, in consultation with one or more federal and state agencies or councils, is a method of establishing appropriate standards for hemp products according to category, condition, cannabinoid profile, THC concentration, or other qualitative and quantitative indicators that one or several federal and state agencies or councils are deemed acceptable or appropriate.

In certain embodiments of the present invention, a hemp product derived from any one or more of the sources described above may be subjected to a variety of testing protocols to determine compliance with federal and state agency and board hemp product labeling guidelines. For example, without limitation, federal agencies that regulate food labeling include the FDA and the USDA. Examples of labeling guidelines include, but are not limited to nutritional panel guidelines, ingredient information and allergen notice, health benefit claim, identity claim, net weight claim, size and label placement requirements, and their combinations. For example, packaging for hemp products for consumption as food must comply with strict requirements from federal and state agencies and councils. By applying certain embodiments of the present invention, time can be saved and costly errors can be avoided as a result of mislabeled food products. By utilizing certain embodiments of the present invention, a professional can review and provide direction and guidance for compliance with regulations. In another example, labeling guidelines include, but are not limited to, guidelines for prescription drugs and biologics for humans, such as active ingredients, possible adverse reactions, and contraindications.

In certain embodiments of the present invention, a hemp product derived from any one or more of the sources described above may be subjected to a variety of testing protocols, identifying appropriate label information, and obtaining labels or protocols to comply with federal and state agency guidelines and councils for the hemp product. For example, without limitation, different hemp products can be consumed in a variety of ways, such as by smoking, vaping, eating a food product, drinking a liquid product, or using injectable, sublingual, or topical formulations. Labeled hemp products for each of these modes of consumption will require rigorous testing of the quality and quantity of required components and undesirable components. Certain embodiments of the present invention include methods and systems for displaying, on hemp products derived from one or more of the sources described above, a set of identifying information associated with hemp products. For example, using certain embodiments of the present invention, it is possible to develop a suitable label or protocol required for the labeling or packaging required to obtain hemp products for consumption. Certain embodiments of the present invention result in a suitable nutritional panel for a hemp product, including, without limitation, a suitable format and content for the panel as required by a regulatory agency or board, such as chemical analysis, caloric analysis, ingredient analysis, and combinations thereof. . Other identifying information associated with hemp products includes the source of the hemp products, the specific hemp plant line, and the quality and quantities of the required ingredients in the hemp product. Information on the label may also include various conditions that can be treated or alleviated by using hemp products, such as, but not limited to, depression, pain, nausea, headaches, insomnia, glaucoma, epileptic seizures, inflammatory bowel disease, lupus, arthritis, Parkinson's disease, post-traumatic stress disorder and muscle spasms. These diseases can be acute or chronic in nature. The information on the label may also include one or more benefits associated with the use of hemp products, such as relief from anxiety or pain, improved lung health, reduced side effects of other drugs, and increased effectiveness of other drugs. In certain embodiments of the present invention, a user may access a database of hemp products and obtain information related to hemp products, nutritional analysis, efficacy profile, source of ingredients, and details related to manufacturers, processors, and retailers associated with a hemp product. .

Certain embodiments of the present invention also include the labeling of hemp products with one or more visual indicators related to the quality and quantity of the desired components in the hemp products. Certain embodiments of the present invention also include the labeling of hemp products with one or more visas.

- 13 040867 al indicators associated with each of the indicated ranges of the amount of the required components in the hemp product. Concentration includes, for example, the amount of a particular chemical component compared to all others from oil and herbal products. Concentrations can be expressed, for example, in one or more of the following ways: weight/weight in percent; volume/weight in percent; volume/volume in percent; weight/volume in percent; percentage of a specific chemical component / total amount of active pharmaceutical ingredients (API); and percent API/total chemical components. Embodiments of the present invention may also be based on components derived from hemp plants or based on cannabinoids in the product. For example, as shown in Table. 1, a food product derived from a hemp line popularly referred to as Pineapple Express contains moderate amounts of tetrahydrocannabinol (THC) but low amounts of cannabidiol (CBD) and cannabinol (CBN). For example, as shown in Table. 2, a hemp product intended to be consumed in a vaporizer or as a smoke, similar to the hemp concentrate derived from the hemp line popularly called Purple Babba Kush, contains high amounts of tetrahydrocannabinol (THC) but low amounts of cannabidiol (CBD) and cannabinol (CBN) . Tab. 1 and 2 are examples and in no way limit the embodiments of the present invention. Other components that can be analyzed and listed on hemp product labels include, but are not limited to, tetrahydrocannabivarin (THCV), cannabichromene (CBC), and cannabicyclol (CBL). Visual indicators may be bar graphs, tables, graphs, symbols, codes, or other graphical representations indicating the relative concentration of one or more components in a hemp product. Visual indicators may also indicate the effectiveness or potency of a particular hemp product in treating or alleviating specific ailments or diseases. Embodiments of the present invention may further include, for example, a reference standard calculated for each cannabis line, as will be appreciated by one skilled in the art, and from which a percentage (%) value of 0 to 50% may be assigned to each of the cannabis component APIs. (with 0 being the lowest and 50 being the highest % concentration value, along with a moderate/medium concentration in the middle). Embodiments of the present invention allow consumers to make informed decisions about which foods to consume or purchase based on desired symptom relief or desired health benefits.

Table 1. Main components of nutritional hemp products from the hemp line - Pineapple Express

Main Components low concentration average concentration high concentration % THC 18% % CBD 0.19% %CBN <0.05%

Table 2. The main components of cannabis concentrates consumed by the use of a vaporizer

Main Components low concentration average concentration high concentration % THC 26% % CBD 0.19% %CBN <0.05%

As an example, an embodiment of the present invention may include an online cannabis testing system or a home testing system. An embodiment of this system includes one or more indicators/processors, an I/O unit, or a device adapted to communicate with one or more processors, one or more cannabis databases in connection with one or more processors, or a stand-alone device. to store and compare a plurality of regulatory rules with a plurality of measurements of the quality and quantity of desired components and undesirable components in a hemp product, one or more electronic interfaces allowing the display of an online report, or a device connecting and defining one or more user interfaces for hemp; and a persistent computer-readable medium mounted in connection with one or more processors and containing one or more computer programs stored thereon. A computer program includes a set of instructions that, when executed by one or more processors, causes one or more

- 14 040867 more operation processors to generate a cannabis user interface showing its user one or more online cannabis reports, wherein the cannabis user interface allows a variety of information related to the user or the hemp product to be entered, to determine if the hemp product satisfies the regulatory rules , taking into account the receipt of a set of information related to the user or a hemp product and information from one or more cannabis databases, match a set of regulatory rules with a set of measurements of the quality and quantity of required components and undesirable components in a hemp product and enter on one or more user cannabis interfaces of one or more online cannabis reports, wherein the cannabis reports include one or more of a variety of information related to the user or cannabis product and one or more of a variety of quality and quantity measurements fucked up components and unwanted components in a hemp product.

Certain embodiments of the present invention combine test results from cannabis data centers with other information related to hemp products and thereby satisfy the public need for standardized information and regulation of legal hemp products. Certain embodiments of the present invention allow the identity, quality, and quantity of the source material, and the desired and undesired components therein, to be traced as the hemp plant feedstock is processed into final hemp products, packaged, and labeled for wholesalers and retailers. Certain embodiments of the present invention permit research or open use, allow federal or state regulatory agencies to regulate consumption, and provide additional guidance for testing and regulation, and make consumers more informed about the product they are buying or consuming. Packaging labeling for regulation and accurate information requires the combination of several analytical tests providing the data and information needed to properly certify a product. Certain embodiments of the present invention provide regulatory agencies with a way to monitor and regulate the legal distribution of hemp products. As an example, an embodiment of the present invention may include measuring the quality or quantity of THC (or other cannabinoids) in foods and certifying or providing a label that indicates that the tested product complies with relevant regulations, such as content of no more than 100 mg of THC in an edible hemp product.

In certain aspects, all testing protocols that determine the qualities and quantities of desired components and undesirable components in hemp products can be carried out in one or more cannabis data centers for research purposes, public use purposes, or combinations thereof. These centers are capable of receiving cannabis product samples from multiple users, subjecting cannabis product samples to appropriate testing protocols, and delivering a wealth of information related to the user or cannabis product. Testing protocols that may be hosted in a cannabis data center include, without limitation, one or more of the following: microbiological testing, food testing, acidified food testing, liquid testing, pathogen testing, additional testing, or their combinations. Testing protocols for a hemp product can be conducted by one or more cannabis data centers. For example, without limitation, one cannabis data center may conduct a subset of testing protocols similar to microbiological testing and pathogen testing, while another data center may conduct nutritional and nutritional testing on the same samples. A cannabis data center may be remote from or host one or more cannabis databases that store multiple regulatory rules with multiple quality and quantity measurements of desired components and undesirable components in hemp products. The hemp data center may also be remote from or host the equipment and personnel required to conduct testing protocols, determining whether hemp products comply with regulatory rules. The hemp data center may also be remote from or host the equipment and personnel required to conduct testing protocols, determining the quality and quantity of required components and undesirable components in hemp products. Cannabis Data Centers may be certified testing centers that comply with the requirements and regulations of state or federal control boards or agencies, including, but not limited to, the USDA, the US Food and Drug Administration, and the Drug Enforcement Administration. .

According to an exemplary embodiment of the present invention, a cannabis data center includes one or more laboratories that have good laboratory practice and current good manufacturing practice established by federal or state agencies, as clear to one skilled in the art to perform testing for

- 15 040867 quality and quality assurance methods. Embodiments of the present invention, including the analysis of hemp and cannabinoid products for research, testing and setting parameters for third parties such as government agencies for grants, public safety, quality control and quality assurance.

Fig. 1 is an illustration of an exemplary embodiment of the methods of the present invention. In one embodiment, the method includes the use of cannabis testing methods 101. In a further embodiment, the cannabis testing methods may be performed in a cannabis data center. Users of this embodiment of the present invention provide samples of their hemp products for testing. These cannabis testing methods 101 determine the quality and quantities of required components and undesirable components in hemp products. Testing protocols include, without any limitation, one or more of the following: microbiological testing, food testing, acidified food testing, fluid testing, pathogen testing, additional testing, or combinations thereof. For example, users of cannabis smoking products 102 may submit their samples for quality control and quality assurance test 103. In certain embodiments of the present invention, users of cannabis pharmaceutical products 104 may submit their samples for quality control and quality assurance test 103. In certain embodiments, users of the hemp food and drink products 106 may submit their samples for quality control and quality assurance testing 107. In certain embodiments of the present invention, users of hemp medical or medicinal products 105 may submit their samples for quality control and quality assurance testing 107 .

In certain embodiments, implementation of the present invention, users may have access to a number of information, recommendations and advisory protocols 109 related to aspects of labeling and regulatory compliance for hemp products submitted for testing. Users of certain embodiments of the present invention may have access to a number of information and protocols 110, including but not limited to protocols relating to origin and processing records, chemical and biological composition of hemp products submitted for testing. Certain embodiments of the present invention include users, such as federal government agencies or councils, having access to information, generating protocols 108, including, but not limited to, protocols related to various hemp products, available in various industries, production volumes and processing of various products, manufacturers of various products and their compliance with laws and regulations. The information from certain embodiments of the present invention, like a database of all product data, is important in helping manufacturers, processors, and retailers maintain or improve their product and their performance in the supply chain, and in deciding which suppliers, processors and merchants can be counted on to meet specific consumer or relevant regulatory or board requirements. In certain embodiments of the present invention, a hemp product derived from any one or more of the sources described above may be subjected to a variety of testing protocols to assist federal and state agencies and boards in conducting safety assessments and recalls of hemp products and other enforcement actions.

Fig. 2 is an illustration of an exemplary embodiment of the methods of the present invention. Samples are provided by users 201 for a quality control test, a quality assurance test, or both a quality assurance test and a quality control test. In certain embodiments of the present invention, these samples may be initially processed 203 for suitable test methods 202. In other embodiments of the present invention, the samples may be directly applied to any of the test methods 202 that determine the quality and quantities of required components and undesired components. Testing protocols include, without any limitation, one or more of the following: microbiological testing, analytical testing, food testing, acidified food testing, fluid testing, pathogen testing, additional testing, or combinations thereof. In certain embodiments of the present invention, these samples are subjected to a microbiological test 204 that determines, for example, without limitation, the presence of microorganisms, the type of microorganisms, the amount, or a combination thereof.

In certain embodiments of the present invention, these samples are subjected to analytical test methods 205 that determine the quality and quantities of desired components and undesired components. Analytical testing, for example, without limitation, may include studies of extracted/leached substances, characterization of a standard sample, elucidation of the structure of target/leader compounds, elucidation of the structure of unknown components, studies of impurities and degradation products, identification and characterization of the composition

- 16 040867 chemical components, synthesis and purification of impurities and decomposition products and elemental analysis of hemp products.

In certain embodiments of the present invention, these samples are subjected to quality control tests 206. Quality control tests ensure that hemp products of high quality, good safety profile, and potency are provided to the public for their good health and the economic benefits derived from the safe hemp trade. products. In certain embodiments of the present invention, the samples subjected to quality control tests range from raw materials to finished products. In certain embodiments of the present invention, testing may be performed to ensure that products at each stage of the hemp product supply chain meet the quality and safety standards specified by the relevant regulatory authorities or councils.

In certain embodiments of the present invention, these samples are subjected to quality assurance tests 207. Quality assurance is a comprehensive program designed to ensure that one or more of the cultivation, production, processing or sale of hemp products or combinations thereof meet minimum quality standards. In certain embodiments of the present invention, this quality assurance ensures that the products of a particular manufacturer, processor, or retailer meet minimum standards set by regulatory bodies or councils. In certain embodiments of the present invention, this quality assurance ensures that the products of a particular manufacturer, processor, or retailer meet appropriate standards set by regulatory bodies or councils. In certain embodiments of the present invention, this quality assurance ensures that the products of a particular manufacturer, processor, or retailer conform to the labeling on the product.

In certain embodiments of the present invention, these samples are analyzed for compliance with labeling and other regulations 208. In certain embodiments of the present invention, hemp products are analyzed for compliance with nutrition panel guidelines, ingredient information and allergen notifications, health claims, statements of identity, statements of net weight, pin requirements and markings, and combinations thereof.

In certain embodiments of the present invention, users may have access to a set of information, records, recommendations, and advisory protocols, collectively described as reports 209, resulting from testing of hemp products. Users of certain embodiments of the present invention may have access to a number of information and protocols 209, including, but not limited to, protocols relating to records of the origin and processing and chemical and biological content of hemp products submitted for testing. Certain embodiments of the present invention include users, such as federal and state agencies or councils, having access to information to obtain protocols 209, including, but not limited to, protocols related to various hemp products available in various industries, production volumes and processing various products, manufacturers of various products and their compliance with laws and regulations.

Certain embodiments of the present invention include systems, a computer-readable software product, and related computerized methods for receiving information from users and generating cannabis reports according to embodiments of the present invention, as discussed above. These embodiments can be implemented using one or more computers, one or more servers, one or more databases, and one or more cloud computing configurations, and one or more communication networks. Certain embodiments of the present invention include a system for collecting a variety of information relating to a hemp product and entering it into a registry. The wealth of information includes, but is not limited to, information relating to hemp production facilities, hemp lines, hemp products, relevant test results and certificates of conformity, hemp processing and distribution systems, and end users. The plurality of information may also include information from an inventory tracking program like Colorado's Marijuana Inventory Tracking Solution (MITS).

Certain embodiments of the present invention include a system with one or more remote electronic interfaces configured to receive selection parameters entered by a user and display a variety of information related to one or more hemp products. The system also has one or more databases that collect and store a variety of information related to one or more hemp products, and one or more processors associated with one or more databases. Data

- 17 040867 processors are configured to receive selection parameters entered by the user through remote electronic interfaces, generate a data packet from a set of information related to the hemp product in the database responsive to the selection parameters entered by the user, and display the data packet to the user in response to the selection parameters entered by the user through remote electronic interfaces.

Embodiments of the present invention may include, for example, the analysis of one or more hemp products, determining the quality and quantity of required components and undesirable components in one or more hemp products, using one or more of the following, for example: cannabinoid profiling, microbiological testing, analytical test, food test, acidified food test, liquid test, pathogen test, quality control test, quality assurance test, or combinations thereof. Embodiments may further include, for example, determining the concentration of one or more cannabinoids and determining appropriate regulations for hemp products, such as relevant government regulations regarding the sale or consumption of hemp products. Embodiments of the present invention may further include comparing the quality and quantity scores of desired components and undesirable components in one or more hemp products with government guidelines for the consumption of one or more hemp products, and generating a protocol, for example, which includes information whether the hemp satisfies product to the relevant regulations.

Fig. 3 is an illustration of a system that is an exemplary embodiment of the present invention. The system may include, for example, a communications network 310, a plurality of electronic interfaces 320, a cannabis testing computer system 300, associated interfaces 302, associated servers 301, and a database 330. One or more modules may operate or control the cannabis testing computer system 300, which includes companion interfaces 302 and companion servers 301, in connection with the database 330, and a plurality of electronic interfaces 320. The communication network 310 may include a telephone network, a wired network, a wireless network, a wide area network, a local area network, an infrared network, a radio frequency network, an optical network, or any cloud computing configurations, or any other communications network currently or hereafter created, as is known and understood by those skilled in the art. Each of the plurality of electronic interfaces 320 allows a human user, such as a manufacturer, data processor, or consumer, to interact with the cannabis testing computer system 300. Each of the electronic interfaces 320 allows a given human user, for example, to enter information related with one or more hemp products as described in the present invention in relation to the hemp testing system. Each of the electronic interfaces 320 allows a given human user, for example, to receive cannabis reports and access related information from the cannabis testing system.

The protocols from the cannabis testing system can be received by the user in a number of formats, including, but not limited to, paper printouts, picture or text messages on a computer or mobile device, electronic messages such as email or text, and other equivalent formats. The output of the cannabis testing system may include other means, including updating an entry in a database, updating a spreadsheet, and sending instructions and/or data to specialized software such as an application on a mobile device, or combinations thereof. In other embodiments, the test system output may include formats and protocols stored on a machine-readable medium (e.g., CD, DVD, USB flash drive, standalone or other removable storage device, computer hard drive or computer network server, etc. .). The output of a cannabis testing system, especially if stored on a computer-readable medium, may be part of a database, which may not necessarily be accessible via the Internet, such as a database of information relating to various hemp products, their associated manufacturers, processors or sellers. stored on a computer network server. The database can be a secure database with security features that restrict access to information related to various hemp products, such as allowing only authorized users to view them.

According to various exemplary embodiments of the present invention, database 330 may be any database structure as is known and understood by one of ordinary skill in the art. The databases discussed in the present invention, including database 330, may be, for example, any form of organized digital data collection. Databases, including database 330, may include a database structure as well as computer programs that provide database services to other computer programs or computers as defined by the client/server model, and any computer designed to run the data. 040867 computer programs (i.e. database server). An exemplary database model, for example, is Microsoft SQL Server 2014 STR2 or SQL Server 2012 or SQL Server 2008 R2. Databases may include a database management system (DBMS) consisting of software that manages the database, provides storage, access, security, backup, and other facilities. A DBMS can support multiple query languages including, for example, SQL, XQuery, OQL, LINQ, JDOQL, and JPAQL. Databases may implement any known database model or database models, including, for example, a relational model, a hierarchical model, a network model, or an object-oriented model. The DBMS may include a data definition language (DDL) for defining a database structure, a data management language (DCL) for defining security/access controls, and a data management language (DML) for querying and updating data. The DBMS may further include interface drivers, which are code libraries that provide methods for preparing statements, executing statements, retrieving results, and so on. Interface driver examples include ODBC, JDBC, MySQL/PHP, FireBird/Python. The DBMS may further include a SQL engine for interpreting and executing DDL, DCL, and DML statements, which includes a compiler, optimizer, and executor. The DBMS may optionally include a transaction mechanism to ensure that multiple SQL statements either succeed or fail as a group, as required by the application. The DBMS may further include a relational engine for implementing relational objects such as tables, indexes, and referential data integrity constraints. The DBMS may further include a storage engine for storing and retrieving data from secondary storage, as well as managing transaction confirmation and rollback, backup and restore, and so on.

Data stored in database fields can be updated as needed, for example by a user with administrative access to the database, to add new data to libraries in the database as they are supported. The person skilled in the art will appreciate that the data described in the present invention as being stored in databases may also be stored or stored in permanent memory and may be accessible among routines, functions, modules, objects, software products or processes, for example, in accordance with objects and/or data variables of routines, functions, modules, objects, software products or processes. Any of the fields of records, tables, libraries, etc. a database may be a multi-dimensional structure, resembling an array or matrix, and may include values or references to other fields, records, tables, or libraries. Any of the above fields can contain either actual values, or a connection, binding, link, or pointer to other local or remote sources for these values.

Database 330 may be, for example, a single database, multiple databases, or a virtual database containing data from multiple sources, such as servers on a worldwide computer network. The hemp database 330 may contain several types of data, including, but not limited to, plant information related to hemp products, plant cultivation information, environmental information, plant maintenance information, raw material processing information, hemp distribution information, product and test results of hemp products. These test results of hemp products may include, without limitation, chemical composition, additive information, microorganism information, cannabinoid profile, nutritional information, and market information. In certain embodiments of the present invention, market information may include historical sales data, sales forecast data, and real-time market prices for raw and processed hemp products across a range of industries. Plant information relating to one or more hemp products in one or more hemp databases includes one or more of the hemp line, seed source, plant genotype and phenotype associated with one or more hemp products, and combinations thereof. Environmental information related to one or more hemp products in one or more hemp databases includes one or more of germination conditions, location, temperature, water, light exposure, and combinations thereof. Plant growing information related to one or more hemp products in one or more hemp databases includes one or more of pesticide application, fertilizer application, growth control, and combinations thereof. Consumer information related to one or more cannabis products in one or more cannabis databases includes purchasing patterns, signs of disease, diagnostic test results, dose, dosage, timing of administration, healthcare prescription data, adverse reaction protocols, protocol of contraindications and therapeutic efficacy. Database 330 may be the inventors' own database, or a database populated with data from a public database, or combinations thereof.

According to various exemplary embodiments of the present invention, for example and as shown in FIG. 3, the cannabis database 330 may be part of the data warehouse. storage

- 19 040867 the data may include other databases, such as a user database, an introduction database, content from or a link to other public databases, a regulation database, and/or a sales database. The user database can be configured, for example, to store any data related to user information, including user names, user addresses, state or federal authorization information, payment records, data related to the user's products or consumption needs, and any other information associated with the user, as is known and clear to a person skilled in the art.

Embodiments include a system for monitoring a hemp product from seed to treatment outcome. As shown in FIG. 4, the system has a general flow through modules that represent information management steps. The first module is the seed module 410, in which seed profiling and characterization takes place. This characterization includes genetic parameters and multi-mix parameters to provide a fingerprint for the hemp product(s) to be obtained. The 410 Seed Module is critical to the traceability and reproducibility of hemp products. The second module is the agricultural module 420 in which monitoring/profiling is done by integrating IT with agricultural tools to collect and track data. There are tools for off-plot tracking (typically 0.5-1 acre plot) or indoor cultivation that monitors agricultural parameters that include temperature, humidity, pressure, along with seed, soil and plant tagging for profiling and detailing growth and development of the hemp product. The next module is a product testing module 430 in which either the crop or the product is processed and tested. The Product Test Module 430 provides laboratory methods that include one or more of the analytical methods like liquid chromatography or gas chromatography (LC/GC), analysis software, data management, and an advanced security feature for crop/product testing. and determining if the product is safe for release to patients. The next module is the product release module 440, in which the product is certified and labelled, and protocols are generated that characterize the product and its relationship to the seed from which it is derived. The product release module 440 manages protocols for distributors, pharmacists, physicians, regulators, and other relevant personnel. The system continues with a patient administration module 450, which includes pharmaceutical formulation, drug formulation, kits, packaging, and imaging conjugation. The patient administration module 450 will be critical to properly manage the next treatment outcome module 460. The next module is the treatment outcome module 460, which monitors the administration of the hemp product to the patient and checks the treatment outcome. The treatment outcomes module 460 includes pharmacists, physicians, and patients with data management system integration that applies federal and state regulatory guidance to patient health information to track and determine treatment outcomes. The treatment outcome module 460 also provides investigators with both validated information and new information to guide the next steps in translational research. In some embodiments, seed module 410, agricultural module 420, product test module 430, product release module 440, patient administration module 450, and treatment outcome module 460 may be placed in any order.

Each module provides information about a specified product, allowing any given step to be correlated with other ways associated with that product. These modules are driven by the integration of information through the blockchain system, providing complete comprehensive information for the provision of any hemp product. In some embodiments, the data collected in each module can be uploaded to the Identifier Blockchain (IBI) 400. As a result, each module can download and share data from other modules that have been uploaded to the Identifier Block 400. In addition, the data uploaded into the BCI module 400 from separate modules can be uploaded to the cloud server 470. In other embodiments, the data collected in each module can be uploaded directly to the cloud server 470. In some embodiments, the BCI unit 400 and the cloud server 470 are integrated into a single unit.

Embodiments include systems and methods for providing a hemp product through a blockchain platform. Systems and methods include seed tracking and testing, planting, harvesting, product, treatment, and distribution to ensure quality control and quality assurance for a safe product for human administration. In some embodiments, the data collected in each module is uploaded to BCI 400 and/or cloud server 470, where BCI 400 and/or cloud server 470 can generate a unique BCI in some predetermined period. BCI may include a blockchain, where a separate block additionally includes timestamps and hash values. The BCH may include a block that includes all of the data loaded by each module. This block may also include the current hash value, which is generated from the data loaded by each module into the current prefix.

- 20 040867 but a certain period. This block may also include the past hash value of the previous block generated just after the current predefined period. Thus, the past hash value serves as a link (hence the term chain) between the previous block and the current block, forming a blockchain. Each block or the entire blockchain included in BCI can be loaded by each module. Thus, each module can download a smaller block or blockchain than downloading all the data uploaded to the BCH block 400 and/or cloud server 470.

Seed module 410 includes systems and methods for obtaining seed data. Systems and methods include obtaining seeds from a source and profiling those seeds. Profiling includes genetic sequencing and multimix analysis to determine the properties of the specified line, forming a data set. The source and dataset generated from the profiling can be loaded into the BCI 400 to generate a unique BCI. The source and dataset generated from the profiling can be uploaded to the cloud server 470 associated with the assigned BHI.

Several characteristics and properties of medical cannabis start with the seeds and their profile. Embodiments include determining the genetic sequence of cannabis seeds to characterize said line. An approved grower will provide seeds for genetic analysis and further characterization such as multi-mix analysis. The genetic profile is used as an identifiable marker for said development of a particular cannabis plant culture. Once the seeds are characterized by their genetic profile, they are assigned a unique identification code, which is subsequently used to access purchases and transfers related to these seeds and their progeny.

In certain embodiments of the present invention, a seed profile may include information that includes genetic sequence, germination, genetic purity, protein and enzyme markers, genotyping, phenotyping, crossing, genus and species identification, among others. Profiling may further include analysis of plant tissue remnants, detection of occurrences of genetic modifications, detection of seed fertilizer applications, seed stability and retention, development of seed quality assurance, evaluation of seed suitability for planting, and seedling growth rate. Profile information is derived from seed testing and/or an existing seed bank that characterizes the seed. Comparative testing can be done on seeds with seed bank profiles to agree on whether there are differences in sequences that have not previously been characterized. Determination of the genetic line is associated with seed profiling, which makes it possible to predict, determine, characterize and compare the profile of cannabinoid products.

In certain embodiments of the present invention, information associated with a number of cannabis seeds is obtained from a breeder or from a seed bank. Information related to seeds corresponding to one line and a particular breeder or seed bank can be stored as a seed record on a blockchain transaction platform. Embodiments include a method of purchasing seeds from a particular cannabis line. The method includes the steps of obtaining a seed request from a grower for a particular hemp line or for seeds that would give a profile of a particular hemp product. Grower related information can be stored as grower records on a blockchain transaction platform. In the next step, a particular seed record is identified in response to the query by comparing the query against the seed records stored in the blockchain transaction platform, and the information from the seed record is passed to the trusted grower to satisfy the query. If a trusted grower wishes to proceed with a financial transaction to purchase seeds that match a suitable seed record, then they can proceed with the purchase. Any financial transaction between a trusted grower and a breeder is stored as a purchase record on the blockchain transaction platform and is linked to a seed record, a grower record, and a breeder record or seed bank. Embodiments of the system also allow trusted parties to edit information from the transaction platform blockchain without causing the transaction platform to crash for its intended purpose. Embodiments include the ability to match and identify the corresponding line that is stored in the system. A grower can request a specific line of cannabis seeds from a breeder. The breeder can then check the seed profile from the record generated from the profile stored on the blockchain platform.

Agricultural module 420 includes systems and methods for collecting plant content data for a particular crop generation. An embodiment of the method would include manually entering fit data and/or capturing fit data with a sensor. Planting data includes soil moisture, air humidity, added or irrigated water, climate control or fluctuations, barometric pressure, light source, nutrients, and pesticides. Embodiments include systems that

- 21 040867 includes devices configured to determine soil and weather parameters, as well as to create records of soil and weather conditions. An exemplary device includes a localization unit with sensors for detection that record soil data and planting parameter data. Sensors that send data to the localization unit can be attached to agricultural tools to directly measure the required plant parameters. Soil parameters include moisture content, nutrient content, micro-organisms and toxic substances. Soil analysis is carried out periodically from planting to harvest. Soil data and planting parameters can be loaded into the BCI 400 to generate a unique BCI associated with a specific hemp line, grower, location and other growing parameters. Soil data and planting parameters can be uploaded to the cloud server 470 associated with the assigned CBI.

Many factors influence crop growth and development outcomes that can enhance or hinder cannabis production, especially factors related to planting and farming practices. Embodiments of the methods and systems include sensors that detect soil moisture, air humidity, plant-derived water, climate control or fluctuations, barometric pressure, light source, nutrients, and pesticides. The seed planting data is dated and timestamped, and manually entered and uploaded to the blockchain the record set for the line of seed sown. Input parameters are also entered, such as the addition of nutrients, the amount of water, or soil analysis. Subsequently, sensors are placed to detect and record the day-to-day factors that promote seed germination and growth. With each detection, the data is uploaded to the BCH 400 and/or the cloud server 470.

A characteristic feature of the reproduction of cannabis plants is the interaction of the roots with the soil. The soil provides the vital nutrients and moisture needed to support sustainable growth to a fully flowering plant. In addition, the soil contains microflora that interacts significantly with the roots of the plant, which helps guide growth. This region of soil is known as the rhizosphere. Embodiments include soil profiling, including moisture levels, nutrients, microorganisms, pesticides, and toxicants. Soil analysis can be performed using the analysis of microorganisms and data entered into the BCI 400 and/or cloud server 470. Subsequently, sensors are placed to detect daily soil changes, where each detection generates data that is uploaded to the BCI 400 and/or cloud server 470 .

In certain embodiments of the present invention, the agricultural module 420 includes sensors that directly measure agricultural parameters to monitor and track plant growth and development. The tools and devices used in the agricultural module 420 can be IT-integrated so that sensors can directly send data to a blockchain-based platform, thus allowing monitoring and tracing during collection, processing and storage to laboratory testing.

Growing cannabis plants can take place both in outdoor environments, such as arable land, and indoors. In many cases, indoor platform systems have been developed to increase control of planting parameters to ensure uniformity and to improve harvest results. Moreover, asexual reproduction using cloning is also being developed for uniform plant production. Embodiments of the present invention include climate and environmental sensors for both outdoor planting and indoor planting. Sensors will perform daily climate and environmental monitoring and capture changes that will generate data that will be uploaded to BCI 400 and/or cloud server 470. In certain embodiments of the present invention, agricultural module 420 includes growth analytics that relate to to the ratio and grouping of the profile of said seed or product.

Cannabis plants are often profiled and classified with simplified descriptions indicating the psychoactive effects of THC, however comprehensive profiling of cannabis plants is much more extensive and correlation with growth analytics is an important part of this analysis. The present invention includes embodiments of correlating growth analytics with cannabinoid profiling results from cannabis plants.

The sensors include a modular unit with sensors that measure various desired parameters, such as a sensor that explicitly measures barometric pressure. The modular block is integrated with the platform by directly sending data to the blockchain platform. For outdoor plants, weather services are integrated for weather forecasting and monitoring to further account for anomalies or changes due to adverse or favorable weather conditions. The platform allows for manual entry of information, where comparison of measured data can resolve inconsistencies. The entire agricultural module 420 receives data that is supposed to be uploaded to the BCH 400 and/or to the cloud server 470 for

- 22 040867 step by step tracking and monitoring from the agricultural process to human consumption.

After the hemp plants are harvested, the plants are processed into the final product. Depending on the application of the plants, the product can be obtained to satisfy the medical, research or recreational markets.

Product testing module 430 includes systems and methods for comprehensive product testing as described in US Pat. No. 9,632,069, incorporated herein by reference in its entirety. The data received from the product test module 430 can be loaded into the BCI 400, generating a unique BCI. The data obtained from the product test module 430 can be uploaded to the cloud server 470 associated with the assigned BFI.

Determining whether a cannabinoid product is safe to administer or consume is one of the main goals of an integrated comprehensive testing module, as it represents the last line of defense before direct human administration. The safety profile, quality control and quality assurance will be key to releasing the product for introduction. Embodiments include a blockchain platform that includes blocks containing information from certain series of tests. Tests include microbiology/pathogens/mycotoxins, pesticides/toxics, residual solvents/liquids, heavy metals, terpene profiling and cannabinoid activity. Testing consistency takes precedence especially when determining whether a medical cannabinoid product is safe for human consumption. The system can apply a pass or fail system based on the standardization of allowable levels of substances. There are industry and government agency thresholds for required and undesirable ingredients in foods and drugs that are not acceptable for human consumption.

Embodiments include systems and methods for testing a hemp crop or product through a series of analytical tests including testing for microbes, pathogens and/or mycotoxins, toxicants, residual solvents and liquids, heavy metals, and cannabinoid content and activity. An example method includes creating data records corresponding to the results of an analytical test. Data records can be loaded into the BCI 400, generating a unique BCI assigned to a particular hemp line, grower, location, and other growth parameters. The data records can be uploaded to the cloud server 470 associated with the assigned BHI.

Embodiments include systems and methods for microbial, pathogenic, and toxicological analysis of a hemp crop or product. An exemplary method includes the steps of analyzing a prepared sample of hemp products for microorganisms, pathogens, and mycotoxins, determining if the sample is safe for further testing. Safety parameters are set based on guidance in accordance with the FDA-CDER in 12/2016 Pharmaceutical Quality/CMC Revision 1 guidelines for the development of botanical medicinal products for industry. At any stage of the analysis, if the sample is considered unsafe, further analysis can be stopped. If the sample is considered safe, further analysis is carried out. The data obtained from the analysis is subsequently uploaded to the BCI 400 block, generating a unique BCI assigned to a specific cannabis crop and trusted growers. The data records can be uploaded to the cloud server 470 associated with the assigned BHI.

Fig. 5 shows an exemplary sequence for a product test module 430. At block 502, a sample with assigned BFI is obtained. The sample can be moved to the testing site and prepared for various testing methods. For example, at block 504, the sample is weighed on a moisture balance to measure moisture content. Knowing the moisture content makes it possible to determine if a sample is prone to mold growth, and the data generated at this stage can be uploaded to the BCI 400 and/or cloud server 470, generating a unique BCI. In block 506, the sample is tested for the presence of microbes/pathogens/mycotoxins. For example, testing can be done with an LC/MS and in a biosafety cabinet, and the data generated at this stage can be uploaded to the BCI unit 400 and/or cloud server 470, generating a unique BCI. Samples are placed in a biosafe cabinet for microbial/pathogen growth determination. This step is very important in this method because a sample that does not have a safe microbiological/pathogenic/mycotoxin profile will not be immediately used in the rest of the test series. At block 508, if the sample does not have a safe microbiological/pathogenic/mycotoxin profile, further testing is stopped. This stop in the testing series is done for two reasons: 1) the product is not safe for consumption and/or 2) the sample may contaminate the rest of the testing system. At block 510, if the sample has a safe microbiological/pathogenic/mycotoxin profile, the sample is subjected to further testing for pesticides and toxicants. Testing can be done by LC/MC; wherein the data generated in this step can be uploaded to the BCI 400 and/or the cloud server 470, generating a unique BCI. At block 512, the sample is tested for residual solvents. Testing can be done by LC/MC where solvents used for extraction, synthesis or preparation may

- 23 040867 be within the content of the product; wherein the data generated in this step can be uploaded to the BCI 400 and/or the cloud server 470, generating a unique BCI. At block 514, the sample is subjected to heavy metal testing. Testing can be performed by the ICP and the data generated at this stage can be uploaded to the BCI 400 and/or cloud server 470, generating a unique BCI. In block 516, the sample is subjected to terpene profiling. Terpene profiling can be done by GC-QP, identifying other components besides cannabinoid products that may be in the product; wherein the data generated in this step can be uploaded to the BCI 400 and/or the cloud server 470, generating a unique BCI. In block 518, the sample is subjected to cannabinoid profiling for components and activity. Cannabinoid profiling can be done by HPLC; wherein the data generated at this stage can be uploaded to the BCH 400 and/or the cloud server 470, generating a unique BCH. Whereas the embodiment described in FIG. 5 provides for the generation of a unique BI ID in each step, other embodiments include generating an ID that is based on previous steps. Other embodiments include generating an ID at each step that invokes the IDs of the previous steps.

Block 510 includes systems and methods for performing a toxicity test on a hemp product. An exemplary method may include preparing a sample of a hemp product for analysis for toxic substances. The data generated from the analysis can be loaded into the BFI 400, generating a unique BFI assigned to a record identifying a cannabis line. The data generated from the analysis can be uploaded to the cloud server 470 associated with the assigned BI. Block 512 includes systems and methods for analyzing residual solvents and liquids of a hemp crop or product. An exemplary method may include analyzing the prepared sample for solvent and liquid content. The data generated from the analysis can be loaded into the BCI 400, generating a unique BCI associated with the specified line that produced the crop or product. The data generated from the analysis can be uploaded to the cloud server 470 associated with the assigned BI. Block 514 includes systems and methods for analyzing a hemp crop or product for heavy metals. An exemplary method may include analyzing the prepared sample for heavy metal content. The data generated from the analysis can be loaded into the BCI 400, generating a unique BCI associated with the specified line that produced the crop or product. The data generated from the analysis can be uploaded to the cloud server 470 associated with the assigned BI. Block 516 includes systems and methods for terpene profiling and analysis of a hemp crop or product. An exemplary method may include analyzing the prepared sample for terpene content. The data generated from the analysis can be loaded into the BCI 400, generating a unique BCI associated with the specified line that produced the crop or product. The data generated from the analysis can be uploaded to the cloud server 470 associated with the assigned BI. Block 518 includes systems and methods for analyzing cannabinoids in a hemp crop or product. An exemplary method may include analyzing a prepared sample for cannabinoid content and activity. The data generated from the analysis can be loaded into the BCI 400, generating a unique BCI associated with the specified line that produced the crop or product. The data generated from the analysis can be uploaded to the cloud server 470 associated with the assigned BI. After the sample has been subjected to a series of tests, it is determined whether the product is safe to release to patients. If the sample is considered safe, the product may be released to patients as shown, for example, by the product release module 440 as shown in FIG. 4 and 5. Products from this representative sample are now certified and can be labeled as such on the packaging from the party providing the product. Optionally, at block 520, the product can be stored for a period of three months to a year, or longer periods as needed. The shelf life of the product can be determined at this stage. After the storage period, a sample from the stored product can be retrieved and retransmitted to complete the entire testing sequence.

Block 520 includes systems and methods for testing the shelf life of a hemp crop or product. An exemplary method may include storing the sample for the required period of time and testing for microbes, pathogens and/or mycotoxins; testing for pesticides and toxic substances; testing for residual solvents and liquids; heavy metal testing; terpene profile analysis and testing of cannabinoid content and activity. At each stage of testing, the data obtained from the test can be loaded into the BCI 400, generating a unique BCI associated with the specified line that produced the crop or product. At each stage of testing, the data resulting from the testing can be uploaded to the cloud server 470 associated with the assigned BI.

Returning to FIG. 4, product release module 440 includes systems and methods for releasing a safe product. Once the sample is found safe in the product testing module 430, the product can be released to patients. Products that pass the 430 product testing module are now certified and can be labeled as they are on the packaging from the side,

- 24 040867 providing the product. It is possible to form protocols that characterize the product and its relationship to the seeds from which it is derived.

In certain embodiments of the present invention, product release module 440 includes distributing a certified product to distributors, pharmacies, clinics, and hospitals. The product can be distributed in recreational retail stores. The product release module 440 manages protocols for distributors, pharmacists, physicians, regulators, and other relevant personnel. The data obtained from the product release module 440 can be loaded into the BCI unit 400, generating a unique BCI associated with the specified line that produced the crop or product. The data obtained from the product release module 440 can be uploaded to the cloud server 470 associated with the assigned BI.

Patient administration module 450 includes systems and methods for administering a released product to a patient. In certain embodiments of the present invention, the patient administration module 450 includes administering a certified product to a patient. The data obtained from the patient administration module 450 can be loaded into the BFI unit 400, generating a unique BFI associated with the specified line that produced the crop or product. The data received from the patient administration module 450 can be uploaded to the cloud server 470 associated with the assigned BHI.

In certain embodiments of the present invention, depending on the purpose of the product, the conjugate may be added to the product for imaging purposes. The conjugate is designed to chelate the radioisotopes in the imaging product. The product containing the conjugate is administered to the patient and radioisotope imaging is performed. Imaging results can be used to confirm treatment outcomes in treatment outcomes module 460.

Embodiments include systems and methods for administering and visualizing a radiolabeled conjugated hemp active pharmaceutical ingredient (API). An exemplary method includes conjugating a hemp API for administration with a cyclam derivative, radiolabeling the conjugated hemp API, administering the radiolabeled conjugated hemp API to a patient, and visualizing the administered radiolabeled conjugated hemp API by various imaging techniques. Imaging modalities include PET, SPECT, CT, MRI, ultrasound, or combinations thereof. The data resulting from the analysis can be loaded into the BFI block 400, generating a unique BFI associated with the specified line that produced the crop or product and associated with the specified patient. The data generated from the analysis can be uploaded to the cloud server 470 associated with the assigned BI.

Treatment outcome module 460 includes systems and methods for monitoring the administration of a patient's cannabis product and validating treatment outcome. The data obtained from the treatment outcome module 460 can be loaded into the BFI block 400, generating a unique BFI associated with the indicated line that produced the crop or product and associated with the indicated patient. The data obtained from the treatment outcome module 460 can be uploaded to the cloud server 470 associated with the assigned BHI.

Embodiments of the present invention include collecting clinical outcome data following administration of a cannabinoid product. Many factors surround the administration of a cannabinoid product that are necessary to determine and compare treatment outcomes. One of the first parameters is patient data, which includes, but is not limited to, genetic profiling, multimix profiling, known disease pathologies, current drug use, demographic and environmental factors. Each patient has a unique set of factors that affect the outcome of treatment. Access to comprehensive, validated seed-to-patient data will allow correlation of treatment outcomes with the individual patient. The patient data is uploaded to the BCI 400 and/or cloud server 470 that is HIPPA compliant. One of the features that this blockchain method provides is a way to monitor the effectiveness of imaging treatments. The medical cannabis API is conjugated to the cyclam derivative, which allows various imaging tracers to complex with the composition and display the biodistribution of the medical cannabis API. The addition of an imaging method provides a way to determine in real time whether medical cannabis is being absorbed into appropriate areas of the tissue or if a product is being excreted. Preferably, the addition of an imaging method can determine if the wrong cannabinol will be administered or if a dosage adjustment is needed. If so, the doctor may change the administration. This treatment result information is uploaded to the BCI unit 400 and/or cloud server 470 for the patient and correlated with the BCI of the line that was collected.

Embodiments include systems and methods for patient profiling. An exemplary method includes obtaining and entering certain data about a patient. Patient profile data includes, but is not limited to, genetic profiling, multi-omics profiling, known disease pathologies, current drug intake, blood work, urinalysis, demographic and environmental factors. Patient profile data can be loaded into the BCI 400 generating a unique BCI associated with a specified patient's compliance with federal and state guidelines, such as the HIPPA guidelines. The patient profile data can be uploaded to the cloud server 470 associated with the assigned BHI.

Embodiments of the present invention allow for significant correlation of patient data, patient administration routes, and clinical outcomes of cannabis administration to be validated by monitoring cannabinoid uptake by imaging in both study and clinical settings. Treatment outcomes are not limited to human patients, but include other animals (in vivo and ex vivo) as well as in vitro assays. The conjugated cannabinoid provides a useful platform to explore cannabinoid products in a way that was not previously available. Linking the treatment outcome to the seed and the patient provides a holistic and personalized way to deliver the drug to the subject. Analysis of the combined information can guide therapy, research, and safety profiles in both a patient-centric and patient-population format. This platform applies a precision medical approach to explore and validate the relationship of agricultural life sciences and product development and distribution, and ultimately to human consumption and health care.

Embodiments of the present invention include methods for incorporating a product into patient-centered care. In one embodiment, patient data from electronic medical records (EMR) systems is not identified and passed to a distributed validated cannabis system, and the data includes a medical review of the patient's profile and response to product administration. EMR devices link screening data to imaging data that confirms the patient's response to administration. The devices provide access to HBI information for the specified product in order to know the entire process that brought the hemp product to the point of administration and further link the data to the outcome of the patient's treatment.

The data generated at each step of the method requires processing, analysis and storage. Embodiments include cloud systems 470 for downloading and storing the data generated in each step of the BFI-bound method. In certain embodiments of the present invention, a computerized method for storing data on a cloud server 470 is described. The cloud server 470 receives a request from a user or device to store data on the server. The cloud server 470 also receives the BCI associated with the data from the user or device. Then, the server determines the processing and analysis based on pre-established correlation algorithms. The server has the flexibility to introduce algorithms for determining correlations. In some solutions, the block BCH 400 and the cloud server 470 are combined into one device.

Embodiments include systems and methods for accessing, activating, displaying BI-related data to an end user with predefined settings and/or recording the end user's identity for any electronic device or computing device used by one or more users. The end user accesses the electronic device, which may have access to the cloud server 470, the electronic device prompts the user to manually enter authentication, identification data and/or BI, and after manually entering these authentication and/or identification data into the electronic device, authentication and/or or the identity is verified by the electronic device, then the data is transmitted to the electronic device from the cloud server 470. End users include, but are not limited to, government, distributors, physicians, patients, pharmacists, gardeners, and researchers.

Embodiments include systems and methods for automating access, activation, output of Blockchain-related BCI data with predefined end user settings. An exemplary system includes an electronic device, a computer device, or a non-volatile medium, including an electronic interface. The electronic interface provides wireless communication with various electronic devices and transfers information to and from the electronic devices to the display. The display is part of an electronic device or is operatively connected to the electronic device being accessed. The electronic device prompts the user to enter a password, display a successful or unsuccessful login, and includes a memory controller that stores information about the user, whereby the user is prompted to enter a password on the display if the information transmitted from the electronic interface indicates that user is an authorized user. The password is checked for correctness and, if it is correct, the password is sent to the electronic interface for transmission and storage on the cloud server 470. The user is automatically allowed access to the electronic device, and / or preset settings for this user are automatically downloaded to the electronic device, if the information transmitted from the electronic interface, indicates that the user has entered the correct password.

A key component of the integration process is the transfer of data from the devices to the cloud server 470 along with the transfer of data between the devices and the interface to any given user. Embodiments of the present invention include the Internet of Things (IoT) for connecting multiple devices to collect, transmit, process, analyze and store data. The transmitted data is associated with the BFI to track and classify the data that is accessed through any interface. The method as described in FIG. 4 focuses on the different data collection access points, which may represent multiple devices that send data to the blockchain block for the specified BCH. Information cannot be changed from an immutable block in the blockchain system, but only verified and validated. Security will be provided to allow the appropriate subject to access the required data or protocol.

Embodiments include a distributed validated system for recording and controlling a hemp product from seed to treatment outcome. Fig. 6 is a schematic representation of blocks created to record and control information related to a hemp product in a distributed validated system. Block 602 is designed to contain the genetic profile of the seeds used in the production of the hemp product. Block 602 is connected to block 604. Block 604 contains the plant growing conditions used in obtaining a hemp product and provides access to information in block 602. Block 604 is connected to block 606. Block 606 contains manufacturing information for obtaining a hemp product and provides access to information at blocks 602 and 604. Block 606 is connected to block 608 and block 610. Block 608 contains storage information regarding the hemp product and provides access to information in blocks 602, 604 and 606. Block 608 is connected to block 610. This block 610 contains information from hemp product testing to determine the quality and quantity of required components and undesirable components in a hemp product, using one or more of cannabinoid profiling, microbiological testing, analytical testing, food testing, acidified food testing, fluid testing, pathogen testing, control quality, quality assurance or any combination of the above. This block 610 also contains information about the concentration of one or more cannabinoids in the hemp product. Block 610 provides access to information in blocks 602, 604, 606, and optionally 608. Block 610 is connected to block 612. Block 612 contains information about whether the hemp product satisfies the relevant rules for consuming a hemp product and provides access to information in blocks 602 , 604, 606, 610, and optionally 608. Block 612 is connected to three blocks 614, 616 and 618. Block 614 contains information about the elimination of a hemp product that does not meet the relevant rules for the consumption of a hemp product, and provides access to information in blocks 602, 604, 606, 610, 612, and optionally 608. Block 616 contains information about the offer and sale of the hemp product as a product for consumer consumption and provides access to the information in blocks 602, 604, 606, 610, 612, and optionally 608. Block 618 contains information about the use or administration of a hemp product by a healthcare professional, such as the dose and dosage of the hemp product the one provided to the patient. Block 618 provides access to information in blocks 602, 604, 606, 610, 612, 620, and optionally 608. Block 620 is also connected to block 618 and contains information about the patient receiving the hemp product, such as symptoms present, diagnosis, and other personal health information. Block 618 is connected to block 622. Block 622 contains information about the outcome of treatment for a patient who is administered a hemp product and provides access to information in blocks 602, 604, 606, 610, 612, 618, 620, and optionally 608.

In one exemplary embodiment, the present invention relates to a method for recording and controlling information related to a hemp product over a distributed validated system. The method includes ensuring that a first authorized user creates a first data set containing a genetic profile of seeds used in obtaining a hemp product. The method includes matching the first set of data with the first record, which is identified by the first unique identifier. The method includes storing a first entry in memory for access by one or multiple authorized users using a first unique identifier. The method includes causing the second authorized user to create a second data set containing the growing conditions of the plants used in obtaining the hemp product. The method includes matching the second set of data with a second record that is identified by a second unique identifier. The method includes storing a second entry in memory for access by one or more of a plurality of authorized users using a second unique identifier, where the second unique identifier provides access to the first data set and the second data set. The method includes ensuring that a third authorized user creates a third data set containing manufacturing information for obtaining a hemp product. The method includes matching a third data set with a third record that is identified by a third unique identifier. The method includes storing a third entry in memory for access by one or more of a plurality of authorized users using a third unique identifier, where the third unique identifier provides access to the first data set, the second data set, and the third data set. The method includes analyzing a hemp product, determining the quality and quantity of required components and undesirable components in a hemp product, applying one or more of cannabinoid profiling, microbiological

- 27 040867 testing, analytical testing, food testing, acidified food testing, fluid testing, pathogen testing, quality control and quality assurance. The method includes determining the concentration of one or more cannabinoids in a hemp product. The method includes ensuring that a fourth authorized user creates a fourth data set containing quality and quantity indicators of desired components and undesirable components in a hemp product. The method includes matching a fourth data set with a fourth record that is identified by a fourth unique identifier. The method includes storing a fourth entry in memory for access by one or more of a plurality of authorized users using a fourth unique identifier, where the fourth unique identifier provides access to the first data set, the second data set, the third data set, and the fourth data set.

This application is a continuation in part of U.S. Patent Application No. 15/470,562, filed March 27, 2017, entitled Integrated Systems and Methods for Evaluating Hemp and Cannabinoid Products for Public Safety, Quality Control, and Quality Assurance, which is a continuation of U.S. Patent Application No. 14 /312051, filed June 23, 2014, now published as U.S. Patent No. 9,632,069 entitled Integrated Systems and Methods for Evaluating Hemp and Cannabinoid Products for Public Safety, Quality Control, and Quality Assurance, which claims benefit and priority of U.S. Provisional Application No. 61/ 936200, filed February 5, 2014, entitled Systems and Methods for Evaluating Hemp Products for Public Safety, Quality Control, and Quality Assurance; and U.S. Provisional Patent Application No. 61/939,385, filed Feb. 13, 2014, titled Systems and Methods for Evaluating Hemp Products for Public Safety, Quality Control, and Quality Assurance, the description of each of which is incorporated by reference in its entirety. This application also constitutes a continuation in part of the 35 U.S.C. § 111(a) of PCT Application No. PCT/US 2018/42707, filed July 18, 2018, entitled Compositions Containing Cannabinoid Analog Conjugates and Methods of Use, which claims the benefit and priority of U.S. Provisional Patent Application No. 62/533894, filed July 18, 2017, entitled Compositions Containing Cannabinoid Analog Conjugates and Methods of Use, the description of each of which is incorporated by reference in its entirety.

Moreover, the foregoing has outlined the objects, features and technical advantages of the present invention and a detailed description of the present invention so that the embodiments of the present invention can be better understood in light of the features and advantages of the present invention as described in the present invention, which are the subject of certain claims of the present invention. It is clear that the concept and the specific embodiment described can be easily applied as a basis for modification or design of other structures to achieve the same objectives of the present invention. It should also be understood that these equivalent constructs are not outside the scope of the present invention as set forth in the appended claims. The new features that are considered to be characteristic of the present invention, both in terms of its organization and mode of operation, together with other objects and advantages, are better understood from the following description when considered in connection with the accompanying figures. However, it should be clearly understood that this description and figures are provided for the purpose of illustration and description only and are not intended to define the limits of the present depiction. A person skilled in the art will appreciate that various modifications and changes can be made within the spirit and scope of the present invention as described in the above description.

Additional modifications and alternative embodiments of various aspects of the compositions and methods described in the present invention will be obvious to a person skilled in the art in view of this description. Accordingly, the present description should be construed as illustrative and is intended to educate those skilled in the art in the general manner of carrying out the embodiments. It should be understood that the forms of embodiments shown and described in the present invention should be considered as examples of embodiments. Elements and materials can be replaced by elements and materials that are illustrated and described in the present invention, parts and methods can be reversed or omitted, and certain features of the embodiments can be applied independently of each other, as all this is obvious to a person skilled in the art after taking advantage of the description of options. implementation. Changes can be made to the elements described in the present invention without departing from the essence and scope of the embodiments, as described in the following claims.

The above description of the methods, compositions and results obtained using them is given merely as an illustrative example. The description of the methods is not intended to require or imply that the steps of the various options must be performed in the order presented. As one skilled in the art will appreciate, the steps in the above embodiments can be performed in any order. Words like then are not meant to be

Claims (6)

limiting the order of stages; these words are simply used to guide the reader through the description of the methods. Many of the operations can be performed in parallel or simultaneously. In addition, the order of operations can be rearranged. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined in the present invention may be applied to other embodiments without departing from the spirit or scope of the present invention. CLAIM 1. A method for recording and controlling information related to a hemp product in a distributed authenticated system, comprising the steps of enabling the first authorized user to create a first set of data containing the genetic profile of seeds used to obtain a hemp product; associating the first data set with the first entry, which is identified by the first unique identifier; storing the first entry in memory for access by one or more of the plurality of authorized users using the first unique identifier; enabling the second authorized user to create a second data set containing the growing conditions of the crop plants used to produce the hemp product; associating the second data set with the second entry, which is identified by the second unique identifier; storing a second memory entry for access by said one or more of the plurality of authorized users using a second unique identifier; enabling a third authorized user to create a third data set containing manufacturing information for obtaining a hemp product; associating the third data set with the third entry, which is identified by the third unique identifier; storing a third memory entry for access by said one or more of the plurality of authorized users using a third unique identifier; analyze the hemp product to determine the quality and quantity of required components and undesirable components in the hemp product using one or more of cannabinoid profiling, microbiological testing, analytical testing, food testing, acidified food testing, fluid testing, pathogen testing, quality control test and quality assurance test; determining the concentration of one or more cannabinoids in the hemp product; both allow a fourth authorized user to create a fourth data set containing quality and quantity indicators of desired components and undesirable components in a hemp product; associating the fourth data set with a quarter entry, which is identified by a fourth unique identifier; storing a fourth memory entry for access by said one or more of the plurality of authorized users using the fourth unique identifier; determine, based on the quality and quantity of required components and undesirable components and the concentration of one or more cannabinoids in the hemp product, whether the hemp product satisfies regulatory guidelines; and correlating whether the hemp product satisfies the regulatory guidelines with the first entry, the second entry, the third entry, and the fourth entry. 2. The method of claim 1, wherein each of the first identifier, second identifier, third identifier, and fourth identifier provides access to one or more of the first data set, second data set, third data set, and fourth data set. 3. The method of claim 1, wherein each of the first entry, second entry, third entry, and fourth entry includes a timestamp. 4. The method of claim 1, wherein each of the steps of storing the first entry, storing the second entry, storing the third entry, and storing the fourth entry is verified by said one or more of a plurality of authorized users. 5. The method of claim 1, wherein the first data set further includes data selected from the group consisting of seed purchase request data, grower data, breeder data, seed purchase data, and combinations thereof. 6. The method of claim 1, wherein the second data set includes data selected from the group consisting of seed planting data, soil data, weather data, water content data, moisture data, pressure data, lighting data, nutrient data, pesticide data, microorganism data, toxics data, crop data -